MRC Centre for Neuropsychiatric Genetics and Genomics

Lead Research Organisation: Cardiff University
Department Name: School of Medicine

Abstract

The main goal of the Centre is to understand how genes are involved in a range of common psychiatric and neurological disorders, and to use this knowledge to improve our understanding of how these diseases arise and to develop new approaches to diagnosis and treatment. We have known for a long time that genes play an important role in disorders such as schizophrenia, bipolar disorder, depression, attention deficit hyperactivity disorder (ADHD), Alzheimer disease and Parkinson disease. Now, using modern genetic technologies, we have begun to identify some of the specific genes involved. Centre scientists have been at the heart of these exciting developments, which have begun to yield novel insights into the brain mechanisms involved, and which have also raised important questions about the validity of current diagnostic approaches. For example our work has shown that intellectual disability, autism, ADHD and schizophrenia are likely to be much more closely related than previously believed. Our success with existing methods, together with the development of new approaches particularly the ability to determine the sequence of DNA (the genetic code) in large numbers of patients, means that we are confident that further work will allow us to identify more of the genes involved in these disorders and that this will deliver greater understanding into how these diseases arise and the relationships between them. Thus a major focus of ours over the next 5 years will be to continue our work aimed at identifying disease genes in these disorders and in understanding how genetic risk operates both across and within current diagnostic categories.

The second major focus of our work will be look at how risk genes lead to illness. This will be essential if we are to understand the mechanisms by which these diseases come about. This work will use a variety of approaches. First, we will look at the impact of risk genes in the general population for example on indexes of brain and cognitive development in the case of psychiatric disorders and on markers of inflammation, and cardiovascular health in the case of Alzheimer disease. This will help us understand how disease develops across the lifespan, and identify potentially modifiable risk factors or makers of those at increased risk of subsequent disease. The latter will be important for future studies aimed at early intervention. Second, we will develop animal and cellular models allowing us to study in detail the impact of risk genes on the function of nerve cells and brain circuits and on behaviour. Finally, we will study in human volunteers and patients how risk genes impact on brain structure and function using brain imaging methods. By studying cells, animals and patients we will be able to link abnormalities in brain function and behaviour seen in patients to abnormalities in cells and brain circuits. This will help us develop methods to stratify patient populations into specific groups for treatment studies as well to understand the mechanisms by which these diseases develop. These advances will be essential if we are to develop novel and more effective treatments for these disabling conditions.

Technical Summary

We have established a Centre of Excellence in psychiatric genetics, focusing on psychiatric and neurodegenerative disorders such as schizophrenia, bipolar disorder, depression, ADHD, Alzheimer disease and Parkinson disease. Over the next 5 years we will retain a strong focus on gene discovery in order to deliver further important insights into disease pathogenesis. We will do this though our clinical, genetic and statistical expertise, our access to suitable patient cohorts, and our proven ability to participate in and provide leadership in large consortia. We will also continue to benefit from our structure of overlapping disease themes supported by a strong genomics, statistical and bioinformatics core. There will be an increasing focus on identifying rare mutations by NGS, and on understanding the significance of genetic findings for risk mechanisms, which will require integration with data from a variety of sources. Moreover, we are now well placed to use genetic findings to obtain greater understanding of pathogenic mechanisms, improve classification, identify biomarkers to aid prediction and intervention and identify novel treatment targets. Broadly speaking this work will take place in two settings. First we will explore the factors that mediate the effects of risk alleles on clinical phenotypes in longitudinal, population-based cohorts and identify biomarkers and modifiable markers of risk through integration of data from other risk factors, gene expression and epigenomics. Second, we will study the impact of risk alleles at molecular, cellular and systems levels through our imaging and cellular/animal models themes. Work in these areas will benefit from our access to patients carrying specific rare, high-penetrance mutations and has been greatly strengthened by our central participation in the Cardiff University Neuroscience and Mental Health Research Institute with which we will be co-located in the new Hadyn Ellis building.

Planned Impact

The main aim of the Centre is to understand how genes are involved in common psychiatric and neurological disorders, and to use this knowledge to improve our understanding of how these diseases arise and to develop new approaches to diagnosis and treatment. The personal and economic burden of these disorders is the largest of all categories of disorder and the development of more effective therapies is a pressing requirement for global health and wellbeing. There will thus be many beneficiaries of our work including sufferers, their families and the wider population upon which much of the economic burden falls. All of the Centre's programmes have specific non-academic impacts linked to their own communications plans. Here we focus on the most immediate areas of impact for the Centre as a whole.

Commercial and Private Sector
The identification of disease risk alleles is of profound interest to molecular, cellular and systems neuroscientists working in the pharmaceutical industry (e.g. Lilly, AZ, Janssen). This allows disease risk to be modeled in systems that are tractable to invasive measurement and intervention, which will be essential in order to identify disease mechanisms and novel drug targets. Those risk alleles that have been identified to date have been the focus of intense industry scrutiny and those emerging from our future work will attract the same level of interest. In addition the rat models we will develop and validate as part of the DEFINE programme will be made available to industry via our agreement with Sigma-Aldrich as will iPSC derived neurons from our patient cohorts via StemBANCC. Our validation of novel animal models of psychiatric disorders will benefit our partners Sigma-Aldrich. Our work on cognition and neuroimaging in relation to genetic risk factors will inform the development of new biomarkers for patient stratification in drug trails and for use as surrogate endpoints in experimental medicine and early phase clinical trials.

Public sector, policy and practice
Our genetics work and theorising has already spearheaded contemporary debate about psychiatric classification and diagnosis. Our future findings on the genetic overlaps and distinctions between current diagnostic groups will continue to inform this debate as psychiatry moves inexorably from the current descriptive system to one that is more in tune with underlying pathogenesis. Our work on genetic and other epidemiological risk markers will be relevant to early diagnosis and identification of those at risk of subsequent psychiatric and neurodevelopmental disorders. These studies will also allow hypothesis-driven studies of causal processes in the general population as well as in clinical samples and longitudinal and quasi-experimental designs. This will inform future intervention policies.

Wider public
Engagement with the general public and with patients and carers is an important part of our mission. This serves not only to communicate our research findings and their relevance but also to address such issues as stigma and the research culture in the NHS in relation to Mental Health. Our commitment to this is based upon our belief that instead of regarding severe mental illnesses as essentially incurable conditions for which the therapeutic focus should be largely palliative, we should regard them as brain disorders which are increasingly tractable to research in genetics, neuroscience, epidemiology etc. We therefore aim to promote research into severe mental illness that focuses not only upon evaluating new models for delivering care but also on understanding pathogenesis and pathophysiology and developing new approaches to treatment.

Skills and Training
We train staff in genetics, statistics, bioinformatics, neuroscience, psychology and psychiatry. Their skills are applicable not only in academia but also more widely including in industry, the NHS, education and policy making.

Organisations

Publications

10 25 50

publication icon
Abu-Akel A (2017) Autistic and schizotypal traits and global functioning in bipolar I disorder. in Journal of affective disorders

publication icon
Agha SS (2017) Parent Psychopathology and Neurocognitive Functioning in Children With ADHD. in Journal of attention disorders

publication icon
Aguirregomozcorta M (2014) Pregnancy and drug use in neurological disease. in Journal of neurology

publication icon
Ahmad S (2018) Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study. in Alzheimer's & dementia : the journal of the Alzheimer's Association

publication icon
Airdrie JN (2018) Facial Emotion Recognition and Eye Gaze in Attention-Deficit/Hyperactivity Disorder With and Without Comorbid Conduct Disorder. in Journal of the American Academy of Child and Adolescent Psychiatry

 
Description Appointed member of National Institute for Health Research Development of a Ten Year Strategy for Mental Health - Children and Young People
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
URL https://www.gov.uk/government/publications/a-framework-for-mental-health-research
 
Description Biomarkers in HD Group
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
URL https://www.ninds.nih.gov/Disorders/All-Disorders/Huntingtons-Disease-Information-Page
 
Description Deputy Director DPUK
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Membership of a guideline committee
 
Description Development of the world's first interactive programme to help sufferers of bipolar disorder better manage their conditions
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact This has allowed those who suffer with bipolar disorder to better manager their conditions.
 
Description Early Intervention for Psychosis in Wales
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact I sit on the Welsh Early Intervention in Psychosis steering and advisory group. This is led by Public Health Wales and oversees a commitment of £1M from Welsh government which has been committed in recent years following consultation and lobbying by the national group on which I am the psychiatric lead.
 
Description European Huntington's Disease Network (EHDN)
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
Impact Aims to improve the quality of life and treatment available to HD patients and their families. Has working groups producing guidelines on specific issues in HD. Has updated genetic counselling and quality of life guidelines in HD in the past. Current initiatives include consideration and production of new guidelines for driving in HD, dysphagia in HD, reporting of incidental findings in HD.
URL http://www.ehdn.org/
 
Description FPWR Pre-Clinical Animal Network
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
URL http://research.fpwr.org/blog/de-risking-pws-drug-development-through-preclinical-screening
 
Description Founded and chair Campaign Working Group for Maternal Mental Health Alliance
Geographic Reach National 
Policy Influence Type Participation in a national consultation
Impact Through Comic Relief Funded campaign "Everyone's Business" - have influenced provision of Perinatal Mental Health Services in UK. With 375 million pounds of new funding being committed to the development of new specialist services.
URL http://everyonesbusiness.org.uk
 
Description Huntington Society of Canada Research Board
Geographic Reach North America 
Policy Influence Type Participation in a advisory committee
URL https://www.huntingtonsociety.ca/
 
Description MQ Funding Priority Setting Meeting on Adolescent Mental Health
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description MRC Expert Group Discussion on Child and Adolescent Mental Health
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description Member FRIMEDBIO Panel 7 (Neuroscience) Research Council of Norway
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
URL https://www.forskningsradet.no/en/Funding/FRIMEDBIO/1208964208385
 
Description Member of Welsh Assembly Government and CAMHS Together for Children and Young People Expert Reference Group
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description Member of the BAP guidelines group on Bipolar Disorder
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
 
Description Member of the Executive Committee on ECT at the RCPsych
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
Impact I am promoting the use of ECT and the use of maintenance ECT in the UK. This has already resulted in better acceptance of these treatments.
 
Description Membership of ARUK grant review board
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description Paper (2016) Thapar A, Cooper M, Rutter M, Neurodevelopmental Disorders: a personal view, The Lancet Psychiatry [Epub ahead of print]
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Paper in Child Psychology Psychiatry entitled "What have we learnt about the causes of ADHD?"
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Paper in The Lancet entitled "Attention Deficit Hyperactivity Disorder" [In Press] 2016
Geographic Reach Europe 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Speaking at V Annual Meeting on Therapeutics in Psychiatry, Barcelona, 2015
Geographic Reach Europe 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Speaking at the Together for Children and Young People Conference, Cardiff, 22 June 2015
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Wellcome Trust Biomedical Resources and Technology Development Board
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
URL https://wellcome.ac.uk/
 
Description Work on the penetrance of CNVs
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
 
Description 1/3 genetic analysis of the international cohort collection for bipolar disorder
Amount £101,154 (GBP)
Organisation National Institute of Mental Health 
Sector Hospitals
Country Sri Lanka
Start 04/2015 
End 01/2018
 
Description 5/7 Psychiatric genomics consortium: Finding actionable variation
Amount £905,712 (GBP)
Organisation National Institutes of Health (NIH) 
Department National Institute of Mental Health (NIMH)
Sector Public
Country United States
Start 06/2016 
End 03/2018
 
Description A detailed clinical-radiological correlation of disability in Multiple Sclerosis
Amount £34,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2015 
End 07/2016
 
Description A device for delivering stem cell therapies to the human brain
Amount £74,812 (GBP)
Organisation European Social Fund (Welsh Government/ EU) 
Sector Public
Country United Kingdom
Start 05/2017 
End 03/2018
 
Description A genetic study of the implications of gender in ADHD and other neurodevelopmental disorders
Amount £250,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2015 
End 01/2019
 
Description A genomic medicine approach to identifying novel drug targets for Parkinson's disease
Amount £45,903 (GBP)
Funding ID Co-applicant 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
End 07/2018
 
Description A genomic medicine approach to identifying novel drug targets for dementia
Amount £45,904 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2017 
End 10/2018
 
Description A high content analysis platform for analysing dementia-associated genetic variation
Amount £108,300 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
End 09/2017
 
Description A long term follow up study for MS patients who have completed the alumtuzumab extension study
Amount £7,467 (GBP)
Organisation Cardiff and Vale University Health Board 
Sector Public
Country United Kingdom
Start 06/2015 
End 05/2020
 
Description A multi-center, open-label study evaluating the safety, tolerability and efficacy of pridopidine in patients with Huntington's disease (open PRIDE-HD)
Amount £3,485 (GBP)
Organisation Cardiff and Vale University Health Board 
Sector Public
Country United Kingdom
Start 05/2016 
End 01/2018
 
Description A phase 2, dose escalating randomised parallel group double blind controlled study evaluating the safety and efficacy of pridopidine twice daily versus placebo for symptomatic treatment in patients with Huntington's disease
Amount £70,220 (GBP)
Organisation TEVA Pharmaceuticals 
Sector Private
Country Israel
Start 11/2014 
End 11/2016
 
Description A phase 2, randomised, placebo-controlled, double blind, proof of concept study of the efficacy and safety of PF-02545920 in subjects with Huntington's Disease
Amount £7,711 (GBP)
Organisation Cardiff and Vale University Health Board 
Sector Public
Country United Kingdom
Start 03/2015 
End 12/2017
 
Description A prospective multicentre observational post authorisation safety to evaluate the long term safety profile of lemtrada treatment in patients with relapsing forms of MS
Amount £3,910 (GBP)
Organisation Cardiff and Vale University Health Board 
Sector Public
Country United Kingdom
Start 11/2015 
End 10/2020
 
Description A prospective, observational study to evaluate quality of life, patient reported outcomes, and safety in patients with relapsing-remitting Multiple Sclerosis who are being treated with Alemtuzumab (Lemtrada) in routine clinical practice
Amount £1,456 (GBP)
Organisation Sanofi 
Sector Private
Country Global
Start 12/2016 
End 12/2019
 
Description A randomised, double blind placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of intrathecally administered ISIS 443139 in patients with early manifest Huntingtons disease
Amount £99,991 (GBP)
Organisation Ionis Pharmaceuticals 
Start 01/2017 
End 12/2019
 
Description A study of prognostic and disease related biomarkers in MS and related disorders
Amount £103,508 (GBP)
Organisation Cardiff and Vale University Health Board 
Sector Public
Country United Kingdom
Start 05/2015 
End 06/2018
 
Description ARUK Wales Network Centre
Amount £40,000 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2017 
End 08/2018
 
Description Adolescent Data Platform - Co-Applicant
Amount £799,963 (GBP)
Organisation MQ Transforming Mental Health 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2018 
End 01/2020
 
Description Adult outcomes of childhood neurodevelopment problems
Amount £20,494 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2015 
End 06/2016
 
Description Advanced pharmacological characterisation of a novel neuroprotective and cognitive enhancer drug for the treatment of neurodegenerative disorders
Amount £49,423 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 08/2018 
End 04/2019
 
Description Alzheimer's Research UK Wales Network Centre
Amount £40,000 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 08/2017
 
Description An observational study of neurocognitive function in patients undergoing stereotactic radiosurgery at Velindre Cancer Centre
Amount £75,000 (GBP)
Funding ID Co-applicant 
Organisation Velindre NHS Trust 
Sector Public
Country United Kingdom
Start 03/2017 
End 02/2019
 
Description An open label extension study to investigate the long term safety, tolerability and efficacy of PF-02545920 in subjects with Huntington's disease who previously completed study A8241021
Amount £33,761 (GBP)
Organisation Cardiff and Vale University Health Board 
Sector Public
Country United Kingdom
Start 10/2015 
End 12/2017
 
Description An open-label extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ISIS 443139 in Huntington's Disease patients who participated in prior investigational studies of ISIS 443139
Amount £57,291 (GBP)
Organisation Ionis Pharmaceuticals 
Start 04/2018 
End 10/2019
 
Description Are Sleep Difficulties in ADHD an index of neurodevelopmental severity? - Co-Applicant
Amount £57,539 (GBP)
Organisation The Waterloo Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 07/2019
 
Description Are astrocytes required for optimal survival and function of dopaminergic implants
Amount £19,812 (GBP)
Funding ID G-1105 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2015 
End 06/2016
 
Description Attention Deficit Hyperactivity Disorder
Amount £250,000 (GBP)
Funding ID Maria Niarchou 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2016 
End 05/2020
 
Description Automated assessment of timing and movement signatures in Huntington's disease
Amount £41,672 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2016 
End 12/2016
 
Description Biological dissection of phenotypic heterogeneity in HD
Amount £100,000 (GBP)
Organisation UK Dementia Research Institute 
Sector Academic/University
Country United Kingdom
Start 10/2018 
End 03/2022
 
Description Biomarkers in pain in Parkinson's disease
Amount £5,000 (GBP)
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2017 
End 08/2017
 
Description Bipolar Education Programme (BEPC)
Amount £5,000 (GBP)
Organisation Baily Thomas Charitable Fund 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2016 
End 10/2017
 
Description Brain Repair and Intracranial Neurotherapeutics - the Wales BRAIN Unit
Amount £1,200,000 (GBP)
Organisation Health and Care Research Wales 
Sector Public
Country United Kingdom
Start 04/2015 
End 03/2018
 
Description Brain Repair and Intracranial Neurotherapeutics - the Wales BRAIN Unit
Amount £800,000 (GBP)
Organisation Welsh Assembly 
Sector Public
Country United Kingdom
Start 04/2018 
End 03/2020
 
Description Cardiff Fetal Tissue Bank
Amount £202,304 (GBP)
Funding ID MR/M02475X/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2015 
End 03/2018
 
Description Cardiff Translational Drug Discovery Centre (CTDDC)
Amount £2,312,749 (GBP)
Funding ID Co-applicant 
Organisation Government of Wales 
Department Welsh European Funding Office
Sector Public
Country United Kingdom
Start 09/2017 
End 08/2022
 
Description Centre for Ageing and Dementia Research (CADR)
Amount £386,341 (GBP)
Organisation Welsh Assembly 
Sector Public
Country United Kingdom
Start 04/2018 
End 03/2020
 
Description Centre for Ageing and Dementia Research (CADR)
Amount £1,200,000 (GBP)
Funding ID 507827 
Organisation Welsh Assembly 
Sector Public
Country United Kingdom
Start 04/2015 
End 03/2018
 
Description Characterisation of a cortical FoxP1
Amount £1,500 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2016 
End 08/2016
 
Description Characterisation of the natural history of HD and assessment of feasibility of HD clinical research within the network of HD clinical centres
Amount £1,151,043 (GBP)
Organisation University Hospital Ulm 
Start 01/2016 
End 12/2018
 
Description Characterising the dynamics of repeat expansion in Huntington's disease
Amount £85,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2018 
End 09/2021
 
Description Characterising the effects of genetic modifiers of Huntington's disease in the R6/1 HD mouse model
Amount £199,788 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2016 
End 09/2019
 
Description Comorbidity and synapse biology in clinically overlapping psychiatric disorders (COSYN)
Amount € 224,500 (EUR)
Funding ID 667301 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 01/2016 
End 12/2020
 
Description DGKH: A key link connecting fatty acid metabolism, stress and bipolar disorder
Amount £128,638 (GBP)
Organisation The Waterloo Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2017 
End 05/2019
 
Description DNA repair in Huntington's disease and other repeat-associated disorders
Amount £150,321 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2016 
End 09/2019
 
Description DRI Costs
Amount £1,123,799 (GBP)
Organisation UK Dementia Research Institute 
Sector Academic/University
Country United Kingdom
Start 09/2017 
End 08/2022
 
Description Deconvoluting the dementia phenotype using functional genomics and computational approaches
Amount £537,913 (GBP)
Organisation Government of Wales 
Department Welsh European Funding Office
Sector Public
Country United Kingdom
Start 01/2018 
End 10/2022
 
Description Dementia Research Institute - Cardiff Centre
Amount £4,658,000 (GBP)
Organisation UK Dementia Research Institute 
Sector Academic/University
Country United Kingdom
Start 05/2017 
End 08/2022
 
Description Dementia Research Institute - Equipment and Capital Award
Amount £4,500,000 (GBP)
Organisation UK Dementia Research Institute 
Sector Academic/University
Country United Kingdom
Start 04/2017 
End 03/2020
 
Description Dementia Research Institute - High Content Imaging Systems
Amount £600,000 (GBP)
Organisation UK Dementia Research Institute 
Sector Academic/University
Country United Kingdom
Start 09/2017 
End 08/2022
 
Description Dementia Research Institute - Studentship
Amount £892,000 (GBP)
Organisation UK Dementia Research Institute 
Sector Academic/University
Country United Kingdom
Start 09/2017 
End 08/2022
 
Description Dementias Platform UK
Amount £1,235,048 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2015 
End 06/2019
 
Description Detecting simple repeat sequences in the genome and their effects in dementias
Amount £48,508 (GBP)
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2018 
End 04/2019
 
Description Determining mortality statistics for Multiple Sclerosis from South Wales registry
Amount £61,368 (GBP)
Organisation Novartis 
Sector Private
Country Global
Start 03/2015 
End 12/2018
 
Description Determining the epidemiology of Multiple Sclerosis
Amount £348,511 (GBP)
Organisation Novartis 
Sector Private
Country Global
Start 09/2016 
End 09/2019
 
Description Determining the mechanisms of striatal dysfunction in SGCE mutation positive myoclonus dystonia using an iPSC-derived neuronal cell model
Amount £717,566 (GBP)
Funding ID MR/P008593/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2017 
End 03/2021
 
Description Developing a cognitive assessment tool for use in NHS psychiatric services
Amount £47,080 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2018 
End 08/2019
 
Description Developing a short animation on what it means to have ADHD
Amount £4,988 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2018 
End 06/2019
 
Description Developing clinical applications for a novel multi-task functional assessment
Amount £49,902 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2016 
End 08/2017
 
Description Developing glioma organ dot cultures
Amount £90,000 (GBP)
Funding ID NC/N002423/1 
Organisation National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) 
Sector Private
Country United Kingdom
Start 10/2016 
End 09/2019
 
Description Developing stem cell technologies for the neurodegeneration of Alzheimer's disease: Assessing the capacity of embryonic stem cell-derived projection neurons and interneurons to integrate in adult cortex
Amount £150,000 (GBP)
Organisation Campaign for Alzheimer's Research in Europe 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2017 
End 09/2019
 
Description Development of head fixed behavioural paradigms to probe neural activity in neurological disease models in the awake brain
Amount £33,833 (GBP)
Funding ID Adam Ranson 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2015 
End 12/2016
 
Description Dynamically networked brain - DyNet-BRAIN: A statistical machine learning approach to dynamic brain connectivity analysis for the extraction of dynamic and multimodal connectomic biomarkers for the diagnosis of psychiatric disorders
Amount £86,904 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 10/2016 
End 12/2019
 
Description Early-onset depression: Characterising development and identifying risks
Amount £763,680 (GBP)
Funding ID MR/R004609/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 11/2017 
End 11/2020
 
Description Effect of APOE genotype on synaptic function in late onset Alzheimer's disease (LOAD)
Amount £59,860 (GBP)
Funding ID Adele Pryce Roberts 
Organisation Alzheimer's Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2016 
End 02/2019
 
Description Ensuring quality maternal care in adverse environment
Amount £505,203 (GBP)
Funding ID BB/P002307/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2016 
End 12/2019
 
Description Establishing post-GWAS pharmaco-MRI: A Multimodal neuroimaging assessment of the molecules and confer genetic risk for psychiatric and neurodegenerative disorders
Amount £85,213 (GBP)
Funding ID Thomas Lancaster 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 03/2019
 
Description Establishing the relationship between anti-microbial host defence and the initiation of tissue fibrosis in peritoneal dialysis
Amount £198,821 (GBP)
Organisation Kidney Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2016 
End 09/2019
 
Description European prevention of Alzheimer's dementia consortium
Amount £104,414 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 01/2015 
End 12/2019
 
Description Examining the effects of four phytocannabinoids (CBD, CBDV, DBDA, THCV (chronic dosing, at a range of doses) on PWS-IC behaviour in a number of tasks
Amount £81,919 (GBP)
Funding ID 20150827 
Organisation GW Pharmaceuticals 
Sector Private
Country United Kingdom
Start 07/2015 
End 03/2018
 
Description Expanding DPUK genetics and integrating with inflammation/immunity research
Amount £100,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2018 
End 03/2019
 
Description Exploring cognitive training as a non-pharmaceutical intervention for people with Huntington's disease
Amount £94,714 (GBP)
Organisation Gossweiler Foundation 
Sector Charity/Non Profit
Country Switzerland
Start 05/2016 
End 09/2017
 
Description Exposing the link between placental endocrine dysfunction and offspring behavioural outcomes
Amount £551,834 (GBP)
Funding ID Co-applicant 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2017 
End 09/2020
 
Description Feasibility Study of a Neurodevelopmental Research Assessment Centre
Amount £287,278 (GBP)
Funding ID 267-2825 
Organisation The Waterloo Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2016 
End 09/2019
 
Description Feasibility of a walking programme for people with Huntington's disease within a city environment
Amount £9,240 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2016 
End 12/2016
 
Description Fetal derived iPS cells as a source of donor cells for a regeneration medicine approach to treating Huntington's disease
Amount £36,875 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2015 
End 03/2017
 
Description Further development and feasibility trial of an online psychoeducational intervention for adolescent depression
Amount £740,642 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 10/2018 
End 09/2022
 
Description Future Minds Programme
Amount £650,000 (GBP)
Organisation The Waterloo Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2018 
End 09/2024
 
Description Gene expression regulation in CD4+ T cell dysfunction in multiple sclerosis
Amount £39,798 (GBP)
Organisation Multiple Sclerosis Society 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2017 
End 09/2018
 
Description Gene regulatory variation in the developing human brain and its role in neuropsychiatric disorders
Amount £245,707 (GBP)
Funding ID MR/L010674/2 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2015 
End 12/2017
 
Description Generating cells for cell replacement therapy in Huntington's: Is FoxP1 important for the production of striatal donor cells
Amount £10,000 (GBP)
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2016 
End 03/2017
 
Description Generation of a human iPSC model of X-linked frontotemporal dementia: modelling proteostasis network dysfunction in dementia
Amount £78,948 (GBP)
Funding ID Co-applicant 
Organisation BRACE (Alzheimer's disease charity) 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
End 07/2018
 
Description How CTIP2 deficiency drives medium spiny neuron degeneration and dysfunction: implications in Huntington's disease pathogenesis
Amount £708,068 (GBP)
Funding ID MR/R022429/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 05/2018 
End 04/2021
 
Description How do cytokines signalling via STAT1 and STAT3 determine the course of synovial inflammation
Amount £898,336 (GBP)
Organisation Versus Arthritis 
Start 11/2015 
End 11/2020
 
Description Human Brain Project
Amount £152,154 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 04/2016 
End 03/2018
 
Description IDEA - Integrated DEmentiA research enviornment
Amount £1,882,982 (GBP)
Funding ID MR/M009076/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2015 
End 03/2016
 
Description IMPC: Characterisation a novel Alzheimer's disease susceptibility locus
Amount £24,317 (GBP)
Funding ID MR/P024939/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 12/2016 
End 11/2018
 
Description INTENSE - Integrated neurotoxicity testing for electrophysiological and neurocellular and seizurogenic effects
Amount £21,861 (GBP)
Organisation National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) 
Sector Private
Country United Kingdom
Start 01/2015 
End 06/2015
 
Description Identification and characterisation of genetic variation that modifies age at onset in Huntington's disease
Amount £82,000 (GBP)
Organisation Cardiff University 
Sector Academic/University
Country United Kingdom
Start 10/2016 
End 09/2019
 
Description Identification of coding variants in DNA repair genes affecting age at onset of Huntington's disease
Amount £18,911 (GBP)
Organisation European Huntington's Disease Network (Euro-HD) 
Sector Charity/Non Profit
Country Germany
Start 08/2016 
End 07/2017
 
Description Identification of genetic modifiers in Huntington's disease
Amount £132,459 (GBP)
Funding ID A-10482 
Organisation CHDI Foundation 
Sector Charity/Non Profit
Country United States
Start 03/2016 
End 02/2018
 
Description Identify new potential cellular targets (pathways, molecules, genes) for therapeutic intervention in schizophrenia
Amount £1,021,691 (GBP)
Organisation Takeda Pharmaceutical Company 
Sector Private
Country Global
Start 10/2018 
End 09/2022
 
Description Identify new potential cellular targets (pathways, molecules, genes) for therapeutic intervention in schizophrenia
Amount £1,021,691 (GBP)
Organisation Takeda Pharmaceutical Company 
Sector Private
Country Global
Start 10/2018 
End 09/2022
 
Description Identifying clinical and cognitive endophenotypes for bipolar disorder: Genetic risk score analysis of tow large poplulation charts
Amount £73,207 (GBP)
Organisation Mental Health Research UK (MHRUK) 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2015 
End 09/2019
 
Description Identifying the contribution of mental disorder risk alleles to childhood neurodevelopment
Amount £237,940 (GBP)
Funding ID MR/M012964/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2015 
End 08/2017
 
Description Identifying the pathogenic triggers of CD8 T cells in multiple sclerosis
Amount £173,892 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2015 
End 08/2017
 
Description Imaging immunity in the genetic risk for Alzheimer's disease
Amount £191,580 (GBP)
Organisation Government of Wales 
Department Welsh European Funding Office
Sector Public
Country United Kingdom
Start 10/2018 
End 09/2021
 
Description In vivo imaging of Tau distribution in the brain
Amount £44,743 (GBP)
Organisation Welsh Local Government Association 
Sector Public
Country United Kingdom
Start 01/2016 
End 03/2017
 
Description Individualising the risk of recurrence for women with bipolar disorder in the perinatal period
Amount £275,769 (GBP)
Funding ID MR/R017557/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 07/2018 
End 08/2021
 
Description Integrated Neuroscience Programme
Amount £865,074 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2015 
End 09/2019
 
Description Integrated Neuroscience Programme
Amount £772,390 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2016 
End 09/2020
 
Description Integrating genetic, clinical and phenotypic data to advance stratification, prediction and treatment in mental health.
Amount £971,676 (GBP)
Funding ID MC_PC_17212 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2018 
End 03/2020
 
Description Integrating genetic, clinical and phenotypic data to advance stratification, prediction and treatment in mental health.
Amount £971,676 (GBP)
Funding ID MC_PC_17212 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2018 
End 03/2020
 
Description Integrating genetic, clinical and phenotypic data to advance stratification, prediction and treatment in mental health.
Amount £971,676 (GBP)
Funding ID MC_PC_17212 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2018 
End 03/2020
 
Description Intellectual disability and mental health: Assessing genomic impact on neurodevelopment (IMAGINE)
Amount £850,450 (GBP)
Funding ID MR/N022572/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 02/2016 
End 07/2019
 
Description Investigating PLCG2 and P522R variant PLCG2 in human IPSC models of dementia
Amount £275,000 (GBP)
Organisation Eisai Inc 
Start 06/2018 
End 05/2020
 
Description Investigating a placental origin for pregnancy and postpartum mood disorders
Amount £719,568 (GBP)
Funding ID MR/M013960/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2015 
End 05/2018
 
Description Investigating alternative immunosuppression regimes to promote survival of human esc-derived dopaminergic grafts for Parkinson's disease
Amount £2,000 (GBP)
Organisation Lister Institute of Preventive Medicine 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2016 
End 07/2016
 
Description Investigating genetic and environmental risk for psychosis mediated through L-Type voltage gated calcium channels
Amount £764,295 (GBP)
Funding ID MR/R011397/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 05/2018 
End 10/2021
 
Description Investigating resilience to schizophrenia in those at genetic risk
Amount £75,040 (GBP)
Organisation Brain & Behaviour Research Foundation 
Sector Charity/Non Profit
Country United States
Start 09/2017 
End 09/2019
 
Description Investigating the association between large rare genetic copy number variants and physical illness in schizophrenia
Amount £30,811 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2015 
End 12/2016
 
Description Investigating the brain role of Setd1a in relation to schizophrenia and developmental disorders
Amount £18,012 (GBP)
Funding ID MR/P026176/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 12/2016 
End 03/2018
 
Description Investigating the early outcomes of child ADHD: Establishing a Wales-wide sample - Co-Investigator
Amount £47,712 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2017 
End 01/2018
 
Description Investigating the potential of the sphingosine-1-phosphate receptor 1 modulators for the treatment of psychiatric disorders
Amount £47,621 (GBP)
Organisation Government of Wales 
Sector Public
Country United Kingdom
Start 10/2015 
End 03/2017
 
Description Investigating the role of gene expression regulation in pathological CD4+ T-cell function in multiple sclerosis
Amount £150,518 (GBP)
Organisation Guarantors of Brain 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2016 
End 07/2019
 
Description Investigating the significance of novel splice variants of the Htt gene in Huntington's disease
Amount £39,900 (GBP)
Funding ID Alis Hughes 
Organisation European Huntington's Disease Network (Euro-HD) 
Sector Charity/Non Profit
Country Germany
Start 01/2015 
End 07/2016
 
Description Investigating the therapeutic potential of manipulating DNA repair in Huntington's disease
Amount £31,184 (GBP)
Organisation European Huntington's Disease Network (Euro-HD) 
Sector Charity/Non Profit
Country Germany
Start 02/2016 
End 01/2017
 
Description Is interneuron transplantation feasible in temporal lobe epilepsy
Amount £30,000 (GBP)
Organisation Epilepsy Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2016 
End 05/2018
 
Description Japan Partnering Award: The generation of eye tissues from human induced pluripotent stem (iPS) cells
Amount £47,959 (GBP)
Funding ID BB/R021244/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 05/2018 
End 04/2022
 
Description Large scale linkage of genetic and health informatics data in schizophrenia to investigate the impact of copy number variants on physical health
Amount £50,000 (GBP)
Funding ID MQDS16/36 
Organisation MQ Transforming Mental Health 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2018 
End 09/2020
 
Description Life-style, exercise and activity package for people living with progressive Multiple Sclerosis
Amount £293,296 (GBP)
Organisation Multiple Sclerosis Society 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2018 
End 01/2021
 
Description Making the invisible visible: Using lived experiences of severe mental illness around childbirth to co-produce tools for individualised pregnancy planning
Amount £66,000 (GBP)
Organisation Health and Care Research Wales 
Sector Public
Country United Kingdom
Start 10/2018 
End 09/2021
 
Description MassArray System: Nucleic Acid detection and Quantification Platform
Amount £115,517 (GBP)
Funding ID SCCEG-05 
Organisation Government of Wales 
Sector Public
Country United Kingdom
Start 04/2015 
End 03/2016
 
Description Miniature microscope to image neuronal ensembles in rodent models of neuropsychiatric disorders
Amount £210,000 (GBP)
Organisation Welsh Local Government Association 
Sector Public
Country United Kingdom
Start 04/2015 
End 03/2016
 
Description Molecular Genetic Studies of Schizophrenia
Amount £2,407,099 (GBP)
Funding ID MR/P005748/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 12/2016 
End 11/2021
 
Description Multi-centre, randomized, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of poesimod to teriflunomide to teriflunomid in subjects with relapsing multiple sclerosis
Amount £26,089 (GBP)
Organisation Cardiff and Vale University Health Board 
Sector Public
Country United Kingdom
Start 07/2016 
End 12/2016
 
Description Multi-scale and multi-modal assessment of coupling in the healthy and diseased brain
Amount £4,953,467 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2016 
End 06/2021
 
Description National Centre for Mental Health
Amount £2,000,000 (GBP)
Organisation Government of Wales 
Sector Public
Country United Kingdom
Start 04/2018 
End 03/2020
 
Description National Centre for Mental Health
Amount £2,000,000 (GBP)
Organisation Welsh Assembly 
Sector Public
Country United Kingdom
Start 04/2018 
End 03/2020
 
Description National Centre for Mental Health
Amount £3,000,000 (GBP)
Organisation Government of Wales 
Sector Public
Country United Kingdom
Start 04/2015 
End 03/2018
 
Description National Centre for Mental Health
Amount £2,000,000 (GBP)
Organisation Welsh Assembly 
Sector Public
Country United Kingdom
Start 04/2018 
End 03/2020
 
Description Neurodevelopmental Disorders: What happens when children grow up and why?
Amount £893,353 (GBP)
Funding ID 204895/Z/16/ZI 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2017 
End 01/2021
 
Description Neuroimmunology fellowship training program
Amount £347,034 (GBP)
Organisation Sanofi 
Department Genzyme Therapeutics Ltd
Sector Private
Country United Kingdom
Start 01/2018 
End 12/2020
 
Description Neuronal mechanisms of developmental cognitive impairment in the Snord1 16del model for Prader-Willi Syndrome
Amount £3,300 (GBP)
Organisation Prader-Willi Syndrome Association 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2019 
End 12/2019
 
Description Neuroscience Research Fellows Programme
Amount £470,637 (GBP)
Organisation The Jane Hodge Foundation 
Sector Charity/Non Profit
Country Unknown
Start 02/2015 
End 08/2020
 
Description Pathways to psychosis: Investigating environmental, cognitive and genetic mechanisms underlying development of psychotic experiences in young adults
Amount £1,062,530 (GBP)
Funding ID MR/M006727/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2015 
End 02/2020
 
Description Physical activity and exercise outcomes in Huntington's disease
Amount £411,005 (GBP)
Funding ID Co-applicant 
Organisation Gossweiler Foundation 
Sector Charity/Non Profit
Country Switzerland
Start 07/2017 
End 12/2019
 
Description Pilot investigation to characterise the in vitro effects of FAN1 in Huntington's disease
Amount £470,460 (GBP)
Organisation CHDI Foundation 
Sector Charity/Non Profit
Country United States
Start 07/2018 
End 06/2020
 
Description Pilot study of motor coordination disorder in 22q11.2 deletion syndrome
Amount £8,935 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2016 
End 12/2016
 
Description Preterm birth and neuropsychiatric genetic risks: a pilot investigation
Amount £291,744 (GBP)
Funding ID MR/N025288/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2016 
End 08/2018
 
Description Profiling post-translational modifications of histone proteins as a determinant of Parkinson's susceptibility
Amount £232,404 (GBP)
Funding ID G-1502 
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2016 
End 07/2018
 
Description Prognosis following early aggressive disease-modifying therapy in MS
Amount £44,696 (GBP)
Organisation Multiple Sclerosis Society 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2016 
End 02/2018
 
Description Promoting neural transplantation-induced brain repair by modulating the local immune environment, using an implantable delivery system
Amount £40,000 (GBP)
Organisation Oakgrove Medical Charitable Trust 
Start 10/2015 
End 09/2018
 
Description Promotion of physical activity in Huntington's Disease clinics
Amount £10,300 (GBP)
Funding ID Co-applicant 
Organisation Huntington's Disease Association England & Wales (HDA) 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2017 
End 03/2019
 
Description Rapid detection and characterisation of life-threatening neurological infections
Amount £24,161 (GBP)
Funding ID Co-applicant 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2017 
End 08/2017
 
Description Real-time MRI neurofeedback market evaluation
Amount £10,258 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 12/2016 
End 12/2016
 
Description Real-time functional magnetic resonance imaging neurofeedback for functional motor recovery after stroke
Amount £54,194 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 08/2015 
End 12/2016
 
Description Stratification of bipolar disorder: Harnessing clinical heterogeneity and genetics shared with other disorders
Amount £310,234 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2018 
End 06/2022
 
Description Stratification of bipolar disorder: Harnessing clinical heterogeneity and genetics shared with other disorders
Amount £310,234 (GBP)
Funding ID Judith Allardyce 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2018 
End 12/2021
 
Description Studentship
Amount £5,000 (GBP)
Organisation Hashemite University 
Sector Academic/University
Country Jordan
Start 10/2018 
End 09/2019
 
Description TG1101-RMS302 Phase III: UbLiTuximab in Multiple Sclerosis treatment effects (ULTIMATE II STUDY)
Amount £5,527 (GBP)
Organisation Cardiff and Vale University Health Board 
Sector Public
Country United Kingdom
Start 01/2019 
End 01/2021
 
Description TRial designs for DElivery of Novel Therapies for Neurodegeneration (TRIDENT)
Amount £184,128 (GBP)
Organisation Health and Care Research Wales 
Sector Public
Country United Kingdom
Start 10/2017 
End 09/2019
 
Description The Hodge Centre for Neuropsychiatric Immunology
Amount £1,021,169 (GBP)
Organisation The Jane Hodge Foundation 
Sector Charity/Non Profit
Country Unknown
Start 02/2017 
End 01/2022
 
Description The Hodge Centre for Neuropsychiatric Immunology
Amount £1,021,169 (GBP)
Funding ID Co-applicant 
Organisation The Jane Hodge Foundation 
Sector Charity/Non Profit
Country Unknown
Start 02/2017 
End 01/2022
 
Description The UK7T network: Developing the ultra-high field MRI platform for biomedical research
Amount £180,843 (GBP)
Funding ID MR/N008537/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2016 
End 12/2018
 
Description The development and implementation of polygenic risk algorithms for stratifying individuals for future cognitive decline due to Alzheimer's disease in non-symptomatic and early cognitive impaired subjects
Amount £288,555 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 03/2018 
End 02/2020
 
Description The development and implementation of polygenic risk algorithms for stratifying individuals for future cognitive decline due to Alzheimers disease
Amount £298,040 (GBP)
Funding ID 2018/20180222 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 03/2018 
End 03/2020
 
Description The impact of rare variants affecting GABA and glutamate gene sets in schizophrenia: An MEG study
Amount £44,206 (GBP)
Organisation Brain & Behaviour Research Foundation 
Sector Charity/Non Profit
Country United States
Start 01/2016 
End 01/2019
 
Description The phenotypic expression of autism spectrum disorder in adults
Amount £29,984 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2018 
End 01/2019
 
Description The phenotypic expression of neuropsychiatric copy number variants
Amount £193,209 (GBP)
Funding ID Kim Kendall 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2017 
End 01/2020
 
Description The phenotypic expression of neuropsychiatric copy number variants
Amount £193,209 (GBP)
Funding ID Kim Kendall 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2017 
End 01/2020
 
Description Therapeutic targeting of impaired lysosomal flux in Alzheimer's disease
Amount £136,502 (GBP)
Funding ID MR/P007651/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 08/2016 
End 07/2018
 
Description To develop, design, promote and evaluate an online community portal and app
Amount £30,000 (GBP)
Organisation Big Lottery Fund 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2015 
End 10/2018
 
Description To establish a scalable set of assay platforms against which the phenotype consequences of manipulating the identified exclusive targets can be screened and effects the drug compounds assessed to develop therapeutics for schizophrenia
Amount £2,960,749 (GBP)
Organisation Takeda Pharmaceutical Company 
Sector Private
Country Global
Start 10/2018 
End 09/2022
 
Description To establish a scalable set of assay platforms against which the phenotype consequences of manipulating the identified exclusive targets can be screened and effects the drug compounds assessed to develop therapeutics for schizophrenia
Amount £2,960,749 (GBP)
Organisation Takeda Pharmaceutical Company 
Sector Private
Country Global
Start 10/2018 
End 09/2022
 
Description To establish a scalable set of assay platforms against which the phenotype consequences of manipulating the identified exclusive targets can be screened and effects the drug compounds assessed to develop therapeutics for schizophrenia
Amount £2,960,749 (GBP)
Organisation Takeda Pharmaceutical Company 
Sector Private
Country Global
Start 10/2018 
End 09/2022
 
Description To establish a scalable set of assay platforms against which the phenotype consequences of manipulating the identified exclusive targets can be screened and effects the drug compounds assessed to develop therapeutics for schizophrenia
Amount £2,960,749 (GBP)
Organisation Takeda Pharmaceutical Company 
Sector Private
Country Global
Start 10/2018 
End 09/2022
 
Description To support families of children with brain disorders by exploiting an embedding new knowledge and capabilities to develop highly innovative solutions and collaborative partnership that bring lasting improvements to the lives of thousands of children
Amount £274,115 (GBP)
Organisation Cerebra 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2019 
End 01/2022
 
Description Tracking Parkinson's - the long term development and analysis of the Parkinson's repository of biomarkers and networked datasets
Amount £125,535 (GBP)
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2016 
End 11/2020
 
Description Training on advanced stem cell technologies in neurology
Amount £484,652 (GBP)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 10/2018 
End 12/2023
 
Description Treading Anxiety to PreEnt Relapse in Schizophrenia (TAPERS) - a feasibility trial
Amount £174,314 (GBP)
Organisation Welsh Assembly 
Sector Public
Country United Kingdom
Start 10/2018 
End 09/2020
 
Description UK DRI at Cardiff
Amount £710,042 (GBP)
Organisation UK Dementia Research Institute 
Sector Academic/University
Country United Kingdom
Start 09/2017 
End 08/2022
 
Description Ultra-high field MRI: Advancing clinical neuroscientific research in experimental medicine.
Amount £6,700,929 (GBP)
Funding ID MR/M008932/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2015 
End 03/2016
 
Description Understanding the role of DNA repair in Huntington's disease pathogenesis: towards novel therapeutic target
Amount £304,780 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 08/2016 
End 07/2019
 
Description Using shape memory scaffolds to increase transplant survival and prepare a nigro/stiratal "bridge"
Amount £28,839 (GBP)
Organisation Parkinson's UK 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2015 
End 10/2017
 
Description Using the smartphone to monitor mood states
Amount £45,775 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2015 
End 11/2016
 
Description Utilising adoption-based research designs to examine the interplay between family relationship processes and child developmental outcomes
Amount £199,868 (GBP)
Organisation Economic and Social Research Council 
Sector Public
Country United Kingdom
Start 01/2015 
End 01/2017
 
Description Validating prognostic biomarkers for colorectal cancer and determining their clinical utility
Amount £155,801 (GBP)
Organisation Cancer Research Wales 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2018 
End 10/2021
 
Title AD Genetics Scotland 
Description Blood samples are collected from participants and sent directly from research sites to European Collection of Authenticated Cell Cultures (ECACC), a Culture Collection of Public Health England. Upon arrival, ECACC process the blood and transform into cell lines- peripheral blood lymphocytes (PBLs) and Lymphoblastoid cell lines (LCLs). Cell lines are frozen and stored at ECACC until they are required by the team at Cardiff. 
Type Of Material Biological samples 
Year Produced 2018 
Provided To Others? No  
Impact Ongoing collection of samples, no publications to date. 
 
Title BAC cell lines 
Description Bacterial method to insert gene mutations of interest into cell lines 
Type Of Material Cell line 
Provided To Others? No  
Impact none yet 
 
Title Brain Bank - Alzheimers 
Description We have recently created a brain bank based upon the longitudinal sample, to provide the wider research community with multiple tissue samples on well characterised individuals. 
Type Of Material Biological samples 
Year Produced 2007 
Provided To Others? Yes  
Impact Multiple publications and media coverage 
 
Title Brains for Dementia Research 
Description Brains; cases and controls 
Type Of Material Biological samples 
Year Produced 2007 
Provided To Others? Yes  
Impact unknown 
 
Title CRISPR generated cell lines 
Description Cell lines created using genome editing tool 
Type Of Material Cell line 
Provided To Others? No  
Impact none yet 
 
Title Calibration 
Description Calibration methods development 
Type Of Material Improvements to research infrastructure 
Provided To Others? No  
Impact ESRC Research methods festival presentation on cross-cohort comparisons, including calibration. Invited Annual Research Review on time trends in press in Journal of Child Psychology and Psychiatry. 
URL http://www.ncrm.ac.uk/RMF2014/home.php
 
Title EOAD cohort 
Description We are collecting a biological sample of early onset Alzheimer's disease individuals for research. This includes phenotypic data and biological data and is set to become the largest EOAD biobank in the world. 
Type Of Material Biological samples 
Provided To Others? No  
Impact This earlier more aggressive form of the disease will be studied in order to shed light on disease mechanisms and prospective therapies. 
 
Title Further developing HiSpot Cultures 
Description Further refinement and validation of HiSpot / OrganDot cultures for studying altered hippocampal neurogenesis in human Temporal Lobe Epilepsy 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2017 
Provided To Others? No  
Impact Paper in Preparation - further validation work in progress 
 
Title Generated a tm1d constitutive Setd1a knockout mouse model 
Description By crossing our Tm1c Setd1a conditional ready knockout model to a CMV-cre (a ubiquitous cre-line) we were able to generate a full (constitutive) Setd1a knockout mouse line free from the targeting construct and markers (such as LacZ) 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2019 
Provided To Others? Yes  
Impact None as yet 
 
Title Generation of conditional-ready (Tm1c) Setd1a knockout 
Description A conditional-ready (Tm1c) knockout mouse model of the schizophrenia and developmental delay gene, Setd1a 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2017 
Provided To Others? Yes  
Impact This model allows us and other researchers to generate region specific knockouts of this key schizophrenia and developmental delay gene 
 
Title Human Stem Cell Modelling of Brain Disease 
Description Cellular models in vitro 
Type Of Material Model of mechanisms or symptoms - in vitro 
Provided To Others? No  
Impact unknown 
 
Title POLARIS 
Description We developed a novel approach to genetic set-based analysis, which accounts for linkage disequilibrium between SNPs and informs the analysis with previously reported effect sizes of a SNP's association to disease. We call this method POLARIS: POlygenic Linkage disequilibrium-Adjusted RIsk Score. 
Type Of Material Improvements to research infrastructure 
Year Produced 2017 
Provided To Others? Yes  
Impact the paper is under review, the software tool is available for testing 
URL http://github.com/BakerEA/POLARIS
 
Title Polygenic score 
Description With 80,000 variants included to create a measure of risk of Alzheimer's disease, the polygenic score is an excellent predictive tool to determine case/control status with high accuracy. The polygenic score encompasses the majority of genetic risk of disease, and can be fine-tuned to identify the pathways involved in disease, for example, immune cell activity or endocytosis. 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2016 
Provided To Others? Yes  
Impact We are working to translate this method from the basic science environment in which it was created into a predictive tool used to select participants for clinical trials, based on their disease status and type. We are currently in discussions with a number of potential collaborators to take this forward. 
 
Title Setd1a-nestin-cre knockout 
Description A knockout of the schizophrenia and developmental delay gene Setd1a limited to nestin expressing cells only. 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2018 
Provided To Others? Yes  
Impact Allows behavioural assessment of thisschizophrenia and developmental delay gene 
 
Title 1000 brains 
Description I have lead the creation of a research resource (database) of around 1000 brain MRI scans and full genomic data to estimulate and facilitate research into neuroimgaing genetics. We make this database freely available to interested researchers within Cardiff University 
Type Of Material Database/Collection of data 
Year Produced 2015 
Provided To Others? Yes  
Impact Two papers have been recently published using this resource: PMID: 26048451 doi:10.1038/tp.2015.195. another paper is currently under revision two further research projects are undergoing using data from the '1000 brains'. 
 
Title Alzhemer's Disease Polygenic Risk Profiling 
Description This model used data from the powerful dataset comprising 17 008 cases and 37 154 controls obtained from the International Genomics of Alzheimer's Project (IGAP). Alzheimer's disease (AD) Polygenic risk scores were generated for 3177 cases and 7277 controls (GERAD data) and tested whether the alleles identified to associate with disease in IGAP sample are significantly enriched in the cases relative to the controls in the GERAD sample. The disease prediction accuracy was investigated in a sample of 3049 cases and 1554 controls (for whom APOE genotype data was available) by means of sensitivity, specificity, area under the receiver operating characteristic curve (AUC) and positive and negative predictive values. The best prediction accuracy AUC = 78.2% (95% confidence interval 77-80%) was achieved by a logistic regression model with APOE, the polygenic score, sex and age as predictors. 
Type Of Material Computer model/algorithm 
Year Produced 2016 
Provided To Others? Yes  
Impact This approach is used to create SNP arrays for AD prediction (for research only so far). 
 
Title DPUK Genomics portal 
Description The DPUK Genetics portal provides a collaborative platform for individuals, DPUK cohorts and the wider research community to share and access research outputs from genetic research. The platform provides two key tools for finding, sharing and analysing genetic data; The Results Registry tool, accessible via the main DPUK web portal, allows searching and uploading of genetic results data. This tool provides a rich set of search tools specific to genetic data and includes visualisation using the popular JBrowse genomic browser. This tool will allow users to share this data. This can be done under secure data transfer agreements if necessary. The second tool is the Genetic Data Browser this is available exclusively within the secure DPUK infrastructure. This will allow users to create cross-cohort comparison studies based on genotypic datasets and linked phenotypic data. This tool provides an interactive dashboard which can pull in phenotypic data and genetic markers from GWAS data and allow users to intuitively explore, combine and export patient cohorts. 
Type Of Material Database/Collection of data 
Year Produced 2017 
Provided To Others? Yes  
Impact The DPUK Genetics portal, housed on the DPUK platform, allows non bioinformatic-expert users to explore components of genetic data within a secure environment. We have provided access to an international consortium, GERAD, via the DPUK data portal. This is a dataset of over 18,000 cases and controls (detailed in Table 2), as well as over 5,600 samples to date submitted to the EADB, the European AD DNA bank for deciphering the missing heritability of Alzheimer's disease 
URL https://portal.dementiasplatform.uk/
 
Title GERAD Exome chip data 
Description Dataset from Illumina Exome chip platform (version 1.0 and v1.1), approximately 6,000 cases and 4,000 controls 
Type Of Material Database/Collection of data 
Year Produced 2014 
Provided To Others? Yes  
Impact papers in press 
 
Title GERAD GWAS 
Description Genome-wide association study data of over 3,000 AD cases and 7,000 controls 
Type Of Material Database/Collection of data 
Year Produced 2009 
Provided To Others? Yes  
Impact multiple publications 
 
Title IGAP dataset 
Description Mega-meta analysis data of over 17,000 AD cases and 30,000 controls 
Type Of Material Database/Collection of data 
Year Produced 2013 
Provided To Others? Yes  
Impact Lambert et al. 2013 (PMID:24162737), Escott-Price et al. 2014(in press), Farrer et al. 2014 (submitted) 
 
Title Identifying CNVs in the UK Biobank 
Description I am caling all CNVs in the 502,000 people from the UK Biobank. These will be made avaialble to the Biobank, for use by researchers from all over the world. 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact This is still on-going and the data have not been uploaded yet (probably late 2016. 
 
Title PGC Pathways 
Description Combining results of several pathway methods on PGC GWAS data 
Type Of Material Data analysis technique 
Year Produced 2015 
Provided To Others? Yes  
Impact Publication 
URL http://www.ncbi.nlm.nih.gov/pubmed/25599223
 
Title Schizophrenia GWAS meta-analysis results 
Description Full genome results of our recent Nature Genetics paper CLOZUK schizophrenia GWAS meta-analysis 
Type Of Material Database/Collection of data 
Year Produced 2018 
Provided To Others? Yes  
Impact has only been active since publication 1 week ago 
URL http://walters.psycm.cf.ac.uk
 
Title Summary statistics for expression quantitative trait loci in the developing human brain and their enrichment in neuropsychiatric disorders 
Description This dataset contains summary statistics for eQTL (Expression Quantitative Trait Loci) analyses using 120 human fetal brains from the second trimester of gestation (12 to 19 post-conception weeks). Expression matrices, covariates, and summary statistics are provided for all tested eQTL and for top eQTL for all genes and transcripts. 
Type Of Material Database/Collection of data 
Year Produced 2018 
Provided To Others? Yes  
Impact As of 12th Feb 2019, the data have been downloaded 135 times in the 2.5 months that they have been available. 
URL https://doi.org/10.6084/m9.figshare.6881825
 
Description ADHD genetics 
Organisation Psychiatric GWAS Consortium (PGC)
Department ADHD Sub Group
Country United States 
Sector Academic/University 
PI Contribution joint papers, samples
Collaborator Contribution joint papers
Impact papers published
Start Year 2007
 
Description Asterand Biosciences 
Organisation Asterand
Country United Kingdom 
Sector Private 
PI Contribution Developing the culture technology for 3D cultures of Huamn Glioma tumours
Collaborator Contribution Potential to commercialise and develop SOPs
Impact N/A
Start Year 2016
 
Description Atmohealth 
Organisation FACE Recording & Measurement Systems Ltd
Country United Kingdom 
Sector Private 
PI Contribution Working with FACE to develop bespoke database solutions for the departments research
Collaborator Contribution developing bespoke database solutions
Impact None to date
Start Year 2016
 
Description BLISS -the preterm birth charity 
Organisation Bliss
PI Contribution WE are working with BLISS as we will do the science and they will conduct focus groups with parents
Collaborator Contribution They will conduct two focus groups
Impact None yet
Start Year 2017
 
Description BRACE 
Organisation University of Bristol
Country United Kingdom 
Sector Academic/University 
PI Contribution advice and training on genomic data analysis
Collaborator Contribution Investigating the genetic overlap between AD and other diseases or traits using polygenic risk scores in Avon Longitudinal Study of Parents and Children (ALSPAC)
Impact 1. Application of newly developed methodology (MR-Base), which hallows to do rapid high-throughput analysis of potentially interesting traits and environmental exposures. 2. Test for shared genetic susceptibility between AD and early life lipid levels, glycaemic, anthropometric, behavioral and cognitive traits in ALSPAC children
Start Year 2016
 
Description Biomarkers for psychosis 
Organisation Royal College of Surgeons in Ireland
Country Ireland 
Sector Learned Society 
PI Contribution Co-app on grant, obtaining data
Collaborator Contribution n/a
Impact HBI Research Grant
Start Year 2014
 
Description Biopsy tissue from glioma. 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of biological samples and clinical data.
Collaborator Contribution Provision of biochemical and genomic analysis.
Impact For publications, either published or in process.
Start Year 2017
 
Description Bipolar 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Grant lead, co-supervising student
Collaborator Contribution n/a
Impact MHRUK studentship and publications
Start Year 2015
 
Description Broad Institute collaboration 
Organisation Broad Institute
Department Stanley Center for Psychiatric Research
Country United States 
Sector Academic/University 
PI Contribution Provided well characterised samples for genotyping.
Collaborator Contribution SNP genotyping and exome sequencing.
Impact none as yet
 
Description CADR 
Organisation Bangor University
Country United Kingdom 
Sector Academic/University 
PI Contribution sample preparation, data analysis
Collaborator Contribution data analysis, sample collections
Impact none yet
Start Year 2014
 
Description CADR 
Organisation Swansea University
Country United Kingdom 
Sector Academic/University 
PI Contribution sample preparation, data analysis
Collaborator Contribution data analysis, sample collections
Impact none yet
Start Year 2014
 
Description CD59 quantification in MS/NMO/CIS/controls 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of biological samples and clinical data
Collaborator Contribution Provision of biological samples and clinical data
Impact For publications, either published or in process.
Start Year 2016
 
Description CFAS 
Organisation Bangor University
Country United Kingdom 
Sector Academic/University 
PI Contribution We are working together with CFAS to prepare the 3,000 participant cohort for genetic research.
Collaborator Contribution Provided cohort
Impact CFAS prepared for Genetic analysis
Start Year 2009
 
Description CFAS 
Organisation Swansea University
Country United Kingdom 
Sector Academic/University 
PI Contribution We are working together with CFAS to prepare the 3,000 participant cohort for genetic research.
Collaborator Contribution Provided cohort
Impact CFAS prepared for Genetic analysis
Start Year 2009
 
Description CLOZUK 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution This has been a 10 year project leading to the acquisition of the largest sample of those with schizophrenia in the world which has led to over 30 publications and multiple grants investigating the genetic basis of schizophrenia, treatment-resistance, adverse effects of antipsychotic treatment and metabolism of these drugs.
Collaborator Contribution These data have been acquired by Cardiff University but through various projects Leyden Delta and King's partners (Dr James MacCabe) have made important contributions to this work.
Impact Grants and many papers have emerged
Start Year 2011
 
Description CLOZUK 
Organisation Leyden Delta BV
Country Netherlands 
Sector Private 
PI Contribution This has been a 10 year project leading to the acquisition of the largest sample of those with schizophrenia in the world which has led to over 30 publications and multiple grants investigating the genetic basis of schizophrenia, treatment-resistance, adverse effects of antipsychotic treatment and metabolism of these drugs.
Collaborator Contribution These data have been acquired by Cardiff University but through various projects Leyden Delta and King's partners (Dr James MacCabe) have made important contributions to this work.
Impact Grants and many papers have emerged
Start Year 2011
 
Description CNV in drug-resitant JME 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of biological samples and clinical data.
Collaborator Contribution Provision of biochemical and genomic analysis.
Impact For publications, either published or in process.
Start Year 2015
 
Description Cell Therapy for Brain repair 
Organisation Cardiff University
Department Brain repair group
Country United Kingdom 
Sector Academic/University 
PI Contribution Demonstration of the effect of the microenvironment on cell transplants
Collaborator Contribution Expertise in animal models of cell transplantation
Impact Life Sciences Bridging Fund grant
Start Year 2015
 
Description Child and Adolescent Research 
Organisation University of Sussex
Department School of Psychology Sussex
Country United Kingdom 
Sector Academic/University 
PI Contribution scientific input to design of grant and ongoing papers
Collaborator Contribution scientific input to design of grant and ongoing papers
Impact Multiple papers
Start Year 2013
 
Description Collaboration with Bristol MRC Unit 
Organisation University of Bristol
Country United Kingdom 
Sector Academic/University 
PI Contribution Joint work on ADHD and risk alleles
Collaborator Contribution ALSPAC data and science
Impact Multiple papers and ongoing collaboration
Start Year 2009
 
Description Collaboration with Eisai AiM Institute 
Organisation Eisai Inc
PI Contribution Consultancy on Polygenic risk score for clinical trials
Collaborator Contribution We are in the process of negotiations
Impact potentially this collaboration will pay for a time of a postdoctoral researcher
Start Year 2018
 
Description Collaboration with NIMH 
Organisation National Institutes of Health (NIH)
Department National Institute of Mental Health (NIMH)
Country United States 
Sector Public 
PI Contribution Joint paper on genetic architecture of irritability.
Collaborator Contribution We jointly have written a paper on findings to do with the genetic architecture of irritability
Impact Paper submitted for publication
Start Year 2016
 
Description Collaboration with the University of Wuerzburg 
Organisation University of Wurzburg
Country Germany 
Sector Academic/University 
PI Contribution We are using my expertise in CNV and sequencing analysis and the German team are contributing their 2000 patients/controls DNA samples
Collaborator Contribution The team in Wuerzburg has collected one of the largest and best-characterised datasets of schizophrenia patients. They are happy to collaborate with us, due to my long-term involvement with their research. We will probably genotype and sequence their samples.
Impact CNV analsyis of de novos: this will make part of a large paper under preparation.
Start Year 2010
 
Description Collaboratiuon with European Bioinformatics institute 
Organisation EMBL European Bioinformatics Institute (EMBL - EBI)
Country United Kingdom 
Sector Academic/University 
PI Contribution We plan to provide a software for polygenic risk score calculation and prosess the GWAS summary statistics for all current GWASes available in EBI GWAS catalogue
Collaborator Contribution provide data access to the GWAS catalogue
Impact This collaboration will provide the GWAS processed data to the research community for quick and efficient calculation of polygenic risk score for any disorder (stored in the EBI GWAS catalogue)
Start Year 2019
 
Description Complement System in MS 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of biological samples and clinical data.
Collaborator Contribution Provision of biochemical and genomic analysis.
Impact For publications, either published or in process
Start Year 2015
 
Description Complement biomarkers in epilepsy 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of biological samples and clinical data.
Collaborator Contribution Provision of biochemical and genomic analysis.
Impact For publications, either published or in process.
Start Year 2016
 
Description DNA genome screening, Illumina 
Organisation University of Bristol
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of biological samples and clinical data.
Collaborator Contribution Provision of biochemical and genomic analysis.
Impact For publications, either published or in process.
Start Year 2016
 
Description DPUK 
Organisation Medical Research Council (MRC)
Country United Kingdom 
Sector Academic/University 
PI Contribution Steering Group member, DPUK work package lead.
Collaborator Contribution Creating Dementia Platform UK Data Portal
Impact In the process of creating on-line database with dementia cohorts, available in the UK and pipelines for data analyses. Multidisceplinary: genetics, bioinfirmatics, IT.
Start Year 2014
 
Description DartingtonSRUresilience 
Organisation Social Research Unit at Dartington
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Informed senior research staff and trustees of findings from the project
Collaborator Contribution Hosted seminar, and agreed to assist in preparation of policy brief and dissemination of findings to local and national stakeholders
Impact Dartington Social Research Unit hosted seminar to discuss findings
Start Year 2015
 
Description De novo mutations in schizophrenia patients 
Organisation University of Wurzburg
Department Department of Psychiatry, Psychosomatics and Psychotherapy
Country Germany 
Sector Academic/University 
PI Contribution A scholar from Germany spent 2 years working in our department. We have worked on genotyping thier collection of 400 families
Collaborator Contribution They provided the DNA samples, part of the funding, work and expertise
Impact An article is being drafted.
Start Year 2011
 
Description Disentangling the population- versus treatment-specific effect on the milder disease course observed during Interferon beta treatment in patients with Multiple Sclerosis 
Organisation Sapienza University of Rome
Country Italy 
Sector Academic/University 
PI Contribution This is a collaboration aimed at disentanginge the population- versus treatment-specific effect on the disease course during IFN beta treatment in patients with MS by testing, in two cohorts belonging to different geographical areas of MS risk (UK and Italy), the impact of demographic and clinical variables that, at the time of treatment commencement, can affect the disease course on treatment and thus can confound the interpretation of treatment influence on clinical outcomes. We will contribute with anonymised patients' data and clinical expertise.
Collaborator Contribution Our collaborators will contribute with with anonymised patients' data and statistical expertise.
Impact No outputs yet.
Start Year 2015
 
Description ENIGMA 
Organisation National Center for Biotechnology Information (NCBI)
Country United States 
Sector Public 
PI Contribution We share and contribute data across different research centres around the world to enhance our statisitical power
Collaborator Contribution We are involved in several projects within ENIGMA: Investigating neuroanatomical biomarkers of Bipolar Disorder. Investigating neuroanatomical abnormalities in psychiatric patients and unaffected relatives. Investigating common genetic variances associated to neuroanatomy.
Impact Two papers have so far resulted from this collaboration: doi: 10.1038/mp.2015.227 doi: 10.1007/s11682-013-9269-5 and several contributions to scientific meetings
Start Year 2014
 
Description EPAD 
Organisation GlaxoSmithKline (GSK)
Department Epidemiology
Country United Kingdom 
Sector Private 
PI Contribution GENOTYPING AND ANALYSIS
Collaborator Contribution cohorts, biomarker studies, epidemiological studies, random control studies
Impact none yet
Start Year 2014
 
Description Early adversity 
Organisation National Institute of Health and Medical Research (INSERM)
Country France 
Sector Public 
PI Contribution Hosted visit and organised seminar; Joint symposium for NCDS@60
Collaborator Contribution Coding of prospectively assessed ACEs in National Child Development Study; Joint symposium for NCDS@60
Impact The long term psychological and physiological consequences of childhood adversities: identifying exposures and pathways over the life course using the NCDS. Paper symposium to be presented at "NCDS 60 years of our lives". London, 2018
Start Year 2017
 
Description Eisai Collaboration 
Organisation Eisai Ltd
Country Japan 
Sector Private 
PI Contribution We are identifying important genes and pathways involved in Alzheimer's disease for further investigation in functional experiments and drug-based tests.
Collaborator Contribution Expertise in functional biology
Impact None yet
Start Year 2015
 
Description EpiPGX - biomarkers in epilepsy 
Organisation University of Dublin
Country Ireland 
Sector Academic/University 
PI Contribution Provision of biological samples and clinical data.
Collaborator Contribution Provision of biochemical and genomic analysis.
Impact For publications, either published or in process.
Start Year 2016
 
Description Eurostemcells 
Organisation EU-T0
Country European Union (EU) 
Sector Public 
PI Contribution Eurostemcells is an educational Consortium to provide reliable information about stem cells and their application including their impact on society. My/my team contribute articles, edit reports and information leaflets.
Collaborator Contribution Coordinated by University of Edinburgh.
Impact Information and reports
Start Year 2014
 
Description Foundation for Prader-Willi Research "Pre-Clinical Animal Network" (FPWR-PCAN) 
Organisation Foundation for Prader-Willi Research (FPWR)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Our expertise has been used to shape the decision making with regards to animal models to be generated and the phenotyping pipeline.
Collaborator Contribution FPWR facilitated the formation and meetings of the FPWR-PCAN and drove the decision-making MRC Harwell, IIT & INMED helped shape the decision making with regards to animal models to be generated and the phenotyping pipeline
Impact Generation of new PWS mouse models by MRC Harwell - these are underway currently
Start Year 2016
 
Description Foundation for Prader-Willi Research "Pre-Clinical Animal Network" (FPWR-PCAN) 
Organisation Italian Institute of Technology (Istituto Italiano di Tecnologia IIT)
Country Italy 
Sector Public 
PI Contribution Our expertise has been used to shape the decision making with regards to animal models to be generated and the phenotyping pipeline.
Collaborator Contribution FPWR facilitated the formation and meetings of the FPWR-PCAN and drove the decision-making MRC Harwell, IIT & INMED helped shape the decision making with regards to animal models to be generated and the phenotyping pipeline
Impact Generation of new PWS mouse models by MRC Harwell - these are underway currently
Start Year 2016
 
Description Foundation for Prader-Willi Research "Pre-Clinical Animal Network" (FPWR-PCAN) 
Organisation MRC Harwell
Department MRC Mammalian Genetics Unit
Country United Kingdom 
Sector Public 
PI Contribution Our expertise has been used to shape the decision making with regards to animal models to be generated and the phenotyping pipeline.
Collaborator Contribution FPWR facilitated the formation and meetings of the FPWR-PCAN and drove the decision-making MRC Harwell, IIT & INMED helped shape the decision making with regards to animal models to be generated and the phenotyping pipeline
Impact Generation of new PWS mouse models by MRC Harwell - these are underway currently
Start Year 2016
 
Description GENAROAD 
Organisation Genetic Architecture of Rate of Alzheimer’s Decline (GENAROAD) Consortium
Country Global 
Sector Charity/Non Profit 
PI Contribution data and analyses
Collaborator Contribution data analysis
Impact none yet, paper being prepared for publication
Start Year 2013
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Albert Ludwigs University of Freiburg
Country Germany 
Sector Hospitals 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Brigham Young University
Country United States 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Central Institute for Mental Health
Country Germany 
Sector Hospitals 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Free University of Berlin
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Friedrich-Alexander University Erlangen-Nuremberg
Department Department of Psychiatry
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation German Centre for Neurodegenerative Diseases
Country Germany 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Goethe University Frankfurt
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Helmholtz Association of German Research Centres
Department Helmholtz Zentrum Munchen
Country Germany 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation King's College London
Department Institute of Psychiatry, Psychology & Neuroscience
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Ludwig Maximilian University of Munich (LMU Munich)
Department Department of Neurology
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Mayo Foundation for Medical Education and Research (MFMER)
Country United States 
Sector Charity/Non Profit 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Medical Research Council (MRC)
Department MRC Centre for Neuropsychiatric Genetics and Genomics
Country United Kingdom 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation National Institutes of Health (NIH)
Country United States 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Oxford University Hospitals NHS Foundation Trust
Department NIHR Oxford Biomedical Research Centre
Country United Kingdom 
Sector Public 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Queen's University Belfast
Department Aging group
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation The Wellcome Trust Sanger Institute
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Trinity College Dublin
Country Ireland 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University College London
Department Institute of Neurology
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University College London
Department MRC Prion Unit and the Dementia Research Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University Duisburg-Essen
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Bonn
Department Department of Psychiatry
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Bristol
Department Dementia Research Group
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Cambridge
Department Cambridge Institute of Public Health
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Hamburg
Country Germany 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Manchester
Department Neuroscience Research Institute (NRI)
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Nottingham
Department Centre for Genetics and Genomics
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Southampton
Department Clinical and Experimental Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation University of Zurich
Department Functional Genomics Centre Zurich
Country Switzerland 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD (Genetic and Environmental Risk in Alzheimer's Disease) 
Organisation Washington University in St Louis
Country United States 
Sector Academic/University 
PI Contribution Leadership, management, DNA from AD cases & controls, Data analysis, directs study design & joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation
Impact Publications: PMED IDs: 19734902; 20862329; 20460622, 21085570, 22005930, 22027014, 21220680, 21460840, 20029910, 22445811, 22693153, 21812096, 22442439, 22430674, 22405046, 23150934
Start Year 2008
 
Description GERAD Exome Chip Consortium 
Organisation Autonomous University of Madrid
Country Spain 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Brigham Young University
Country United States 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Cardiff University
Department School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Fondazione Santa Lucia
Country Italy 
Sector Hospitals 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Hospital de Sant Pau
Country Spain 
Sector Hospitals 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Ludwig Maximilian University of Munich (LMU Munich)
Country Germany 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Neuroscience; IOP
Country United Kingdom 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Queen's University Belfast
Department Aging group
Country United Kingdom 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation Saarland University
Country Germany 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University College London
Department MRC Prion Unit
Country United Kingdom 
Sector Public 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Bonn
Department Department of Psychiatry
Country Germany 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Cantabria
Country Spain 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Navarra
Country Spain 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Nottingham
Department Centre for Genetics and Genomics
Country United Kingdom 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Oviedo
Country Spain 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Southampton
Department Clinical and Experimental Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GERAD Exome Chip Consortium 
Organisation University of Washington
Country United States 
Sector Academic/University 
PI Contribution Leads the (GERAD) consortium, management, DNA from AD cases and controls, access to exome chip data from elderly, screened controls, data ananlysis, directs study design
Collaborator Contribution DNA from AD cases and/or controls, access to exome chip data from population controls, input into study design, input into manuscript preparation
Impact Exome chip paper replication on just under 90k subjects is in preparation (submitted to Nature Genetics Letters).
Start Year 2012
 
Description GW Pharmaceuticals 
Organisation GW Pharmaceuticals
Country United Kingdom 
Sector Private 
PI Contribution Using data acquired under previous grants to guide research into potential therapeutics
Collaborator Contribution Providing therapeutics (subject to confidentiality agreement) for testing
Impact Research contract funding
Start Year 2015
 
Description GW4 epigenetics consortium 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund
Collaborator Contribution Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund
Impact Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Commitment to apply for GW4 Accelerator funding to establish an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Initiator fund
Start Year 2014
 
Description GW4 epigenetics consortium 
Organisation University of Bath
Department Department of Biology and Biochemistry
Country United Kingdom 
Sector Academic/University 
PI Contribution Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund
Collaborator Contribution Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund
Impact Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Commitment to apply for GW4 Accelerator funding to establish an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Initiator fund
Start Year 2014
 
Description GW4 epigenetics consortium 
Organisation University of Bristol
Country United Kingdom 
Sector Academic/University 
PI Contribution Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund
Collaborator Contribution Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund
Impact Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Commitment to apply for GW4 Accelerator funding to establish an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Initiator fund
Start Year 2014
 
Description GW4 epigenetics consortium 
Organisation University of Exeter
Country United Kingdom 
Sector Academic/University 
PI Contribution Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund
Collaborator Contribution Overview of Research Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Discussion of establishing an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Accelerator fund
Impact Discussion of proposal for GW4 Epigenetics consortium doctoral training scheme, how this would be structured and where to go for further funding. Commitment to apply for GW4 Accelerator funding to establish an "GW4 Epigenetics club" for junior scientists to discuss research; application for this from the GW4 Initiator fund
Start Year 2014
 
Description GW4 fellowship 
Organisation Cardiff University
Department Brain Research Imaging Centre (CUBRIC)
Country United Kingdom 
Sector Academic/University 
PI Contribution co-supervisor; advice and training on genomic data analysis
Collaborator Contribution A researcher, Judith Harrison
Impact To explore disease pathways in Alzheimer's disease using MRI Biomarkers and Polygenic Scores
Start Year 2017
 
Description Gene expression in Huntington's disease 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Analysis of gene expression data.
Collaborator Contribution generation of gene expression data
Impact 10.1093/hmg/ddw142, 10.1038/srep44849 . multidisciplinary - biostatistics/bioinformatics/molecular biology
Start Year 2013
 
Description Genetic Modifiers in Huntington's disease 
Organisation Massachusetts General Hospital
Department Centre for Human Genetic Research
Country United States 
Sector Hospitals 
PI Contribution I am the European lead of the Genetic Modifiers in Huntington's disease (GeM-HD) collaboration. They pay for an analyst in my research group.
Collaborator Contribution The partners conduct the genotyping for this project and also perform some analysis.
Impact Keum, J.et al. 2016. The HTT CAG expansion mutation determines age at death but not disease duration in Huntington's Disease. American Journal of Human Genetics 98(2), pp. 287-298. pdf Lee, J.et al. 2015. Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. Cell 162(3), pp. 516-26. (10.1016/j.cell.2015.07.003) Correia, K.et al. 2015. The Genetic Modifiers of Motor OnsetAge (GeM MOA) Website: Genome-wide Association Analysis for Genetic Modifiers of Huntington's Disease. Journal of Huntington's Disease 4(3), pp. 279-284. (10.3233/JHD-150169) . http://dx.doi.org/10.1093/hmg/ddx286; doi: 10.1038/ejhg.2017.
Start Year 2010
 
Description Genetics of trinucleotide repeat disorders 
Organisation University College London
Department Institute of Neurology
Country United Kingdom 
Sector Academic/University 
PI Contribution I led a collaboration investigating whether the genetic modifiers of Huntington's disease also acted as modifiers in other repeat disorders
Collaborator Contribution DNA from subjects with trinucleotide repeat disorders, genotyping.
Impact Jones, L., Houlden, H. and Tabrizi, S. J. 2017. DNA repair in the trinucleotide repeat disorders. The Lancet Neurology 16(1), pp. 88-96. (10.1016/S1474-4422(16)30350-7) pdf Bettencourt, C.et al. 2016. DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases. Annals of Neurology 79(6), pp. 983-990. (10.1002/ana.24656) pdf
Start Year 2015
 
Description Genomics England 
Organisation Genomics England
Country United Kingdom 
Sector Public 
PI Contribution We are in the very early stages of discussion with Genomics England, but we hope to be able to use their facilities for whole Genome sequencing. This will mean that we generate valuable data on the largest EOAD cohort world-wide.
Collaborator Contribution Genomics England have the equipment and infrastructure set up for the very expensive and technical whole exome sequencing.
Impact None yet
Start Year 2015
 
Description GlaxoSmithKline Cardiff Collaboration 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Prof Williams made contact with a GSK rep at the Global Genetics Congress in Baltimore, September 2016. GSK were extremely interested in collaborating with the Cardiff team. Specifically, GSK have an interest in the latest confidential experimental results and translating these from genetic to biological meaning. This will speed up the Cardiff Team's discovery of potential molecular targets for personalised disease treatment. Cardiff will contribute expertise in Alzheimer's disease genetics.
Collaborator Contribution GSK will contribute their expertise in disease models and drug mechanisms.
Impact This collaboration has been brought under a confidentiality agreement. Parties involved are experts in genetics and functional biology.
Start Year 2016
 
Description Graves disease, alemtuzamab patients 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of biological samples and clinical data.
Collaborator Contribution Provision of biochemical and genomic analysis.
Impact For publications, either published or in process.
Start Year 2015
 
Description HCRW Brain Repair and Intracranial Neurotherapeutics (B.R.A.I.N.) Unit 
Organisation Health and Care Research Wales
Country United Kingdom 
Sector Public 
PI Contribution Director of BRAIN Unit
Collaborator Contribution Supported Bionbanking, R&D regulation, Technician support for Human tissue Biobanking, Suport of Clinical Research Fellow for consent and Tissue Collection
Impact Research just commenced.
Start Year 2016
 
Description HD modifiers 
Organisation CHDI Foundation
Country United States 
Sector Charity/Non Profit 
PI Contribution Analysis of genome-wide HD data
Collaborator Contribution Provision of data, paying salary of researcher
Impact Analysis of genome-wide HD data
Start Year 2015
 
Description Identifying the pathogenic triggers of CD8 T-cels in MS 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of biological samples and clinical data.
Collaborator Contribution Provision of biochemical and genomic analysis.
Impact For publications, either published or in process.
Start Year 2015
 
Description Informed Consent for DMTs in MS 
Organisation International Multicentre persistent ADHD CollaboraTion (IMpACT)
Country Global 
Sector Academic/University 
PI Contribution I am contributing to write information sheets and informed consents for DMTs in MS.
Collaborator Contribution My collaborators are also contributing to the writing of these information and consents
Impact No outputs yet.
Start Year 2014
 
Description Informed consent for disease modifying treatments in MS 
Organisation Sapienza University of Rome
Country Italy 
Sector Academic/University 
PI Contribution Multicentre collaboration to gain an international consensus on informed consent for disease modifying treatments in MS. I contributed to the project by drafting consent forms for patients and by participating to workshops and discussions of the group.
Collaborator Contribution Intellectual contribution and medico-legal revision of the documents.
Impact This is a multidisciplinary collaboration. The consensus group has drafted informed consents for the licensed disease modifying treatments in MS.
Start Year 2014
 
Description Innovate UK 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Consultancy
Collaborator Contribution Design of Alzhemer's disease chip
Impact In the process of designing of Alzhemer's disease SNP array. Multidisceplinary: medical genetics, bioinformatics, statistics
Start Year 2015
 
Description International Genomics of Alzheimer's Project (IGAP) 
Organisation Boston University
Country United States 
Sector Academic/University 
PI Contribution Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis
Impact papers in progress
Start Year 2012
 
Description International Genomics of Alzheimer's Project (IGAP) 
Organisation Genetic and Environmental Risk in Alzheimer's Disease (GERAD)
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis
Impact papers in progress
Start Year 2012
 
Description International Genomics of Alzheimer's Project (IGAP) 
Organisation University of Lille
Country France 
Sector Academic/University 
PI Contribution Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis
Impact papers in progress
Start Year 2012
 
Description International Genomics of Alzheimer's Project (IGAP) 
Organisation University of Pennsylvania
Department Alzheimer's Disease Genetics Consortium (ADGC)
Country United States 
Sector Learned Society 
PI Contribution Co-leadership, management, DNA from AD cases and controls, GWAS data from AD cases and controls, data analysis and joint papers
Collaborator Contribution DNA from AD cases and/or controls, GWAS data from AD cases and/or controls, input into study design, input into manuscript preparation, data analysis
Impact papers in progress
Start Year 2012
 
Description International Multiple Sclerosis Genetics Consortium 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution Provision of DNA from an established patient cohort.
Collaborator Contribution Genomic analysis
Impact Numerous publications
Start Year 2014
 
Description International Multiple Sclerosis Genetics Consortium 
Organisation University of California, San Francisco
Department School of Medicine (UCSF)
Country United States 
Sector Academic/University 
PI Contribution Provision of DNA from an established patient cohort.
Collaborator Contribution Genomic analysis
Impact Numerous publications
Start Year 2014
 
Description International Multiple Sclerosis Genetics Consortium 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of DNA from an established patient cohort.
Collaborator Contribution Genomic analysis
Impact Numerous publications
Start Year 2014
 
Description JPND PERADES 
Organisation JPND Research
Country Global 
Sector Academic/University 
PI Contribution Coordinator of the EU Joint Programme - Neurodegenerative Disease Research PERADES project
Collaborator Contribution Containing researchers from 11 countries. Exploiting new statistical approaches to genetic data, researchers will calculate polygenic risk scores and use these to identify individuals at both high and low risk of developing Alzheimer's disease.
Impact The JPND project brings together researchers across Europe to perform vast replication studies of variants of interest in Alzheimer's disease. The project is also the first to begin exome sequencing of the EOAD cohort, which we hope will shed light on the early stages of disease. Importantly, this project brings together the areas of genetics, a variety of omics, polygenic scores, and population studies in a powerful combination to further our knowledge of Alzheimer's disease.
Start Year 2013
 
Description Jackson labs collaboration 
Organisation The Jackson Laboratory
Country United States 
Sector Charity/Non Profit 
PI Contribution We provide the most up to date genetic human Alzheimer's disease study results and interpretation.
Collaborator Contribution Jackson labs provide their expertise in translation of human study findings into small animal transgenic models of genetic diseases.
Impact Attempts so far to tie down both a project plan and committed funding, have not been successful. We are currently exploring alternative methods to whole animal experiments. We hope that in the future we will be able to regenerate interest in this promising collaboration.
Start Year 2016
 
Description MRC AD Cohort 
Organisation King's College London
Department Institute of Psychiatry, Psychology & Neuroscience
Country United Kingdom 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation Medical Research Council (MRC)
Department MRC Centre for Developmental Neurobiology
Country United Kingdom 
Sector Public 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation Trinity College Dublin
Country Ireland 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation University of Cambridge
Department Department of Medical Genetics
Country United Kingdom 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC AD Cohort 
Organisation University of Cambridge
Department Department of Public Health and Primary Care
Country United Kingdom 
Sector Academic/University 
PI Contribution We contributed DNA, clinical follow up information, genotyping and other laboratory work and complex data analysis.
Collaborator Contribution The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question. The MRC AD cohort was collected with MRC funding in a previous grant. This collaboration continues to function looking at candidate genes and candidate regions testing for association with AD and further enriching our clinical data longitudinally, on the remaining members of the cohort. A proportion of this research was directly funded by the MRC grant in question.
Impact 16970641 17322133 17530621 17440948 17440933 17373700 17999207 18163421
 
Description MRC fellowship 
Organisation University of Bristol
Country United Kingdom 
Sector Academic/University 
PI Contribution advice and training on genomic data analysis
Collaborator Contribution A researcher, Dr. Emma Anderson, who is a highly productive junior researcher
Impact 1. To improve causal inference in mendelian randomization studies of dementia 2. To improve understanding of the genetic risk for dementia and trajectories of cognitive capabilities in aging 3. To identify modifiable risk factors that are related to dementia and cognitive decline
Start Year 2016
 
Description Measuring complement activation in diagnosis and management of neuromyelitis optica 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of biological samples and clinical data.
Collaborator Contribution Provision of biochemical and genomic analysis.
Impact For publications, either published or in process.
Start Year 2014
 
Description Metabolomics study 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of biological samples and clinical data.
Collaborator Contribution Provision of biochemical and genomic analysis.
Impact For publications, either published or in process.
Start Year 2016
 
Description NIMH fellowship partnerships 
Organisation National Institutes of Health (NIH)
Department National Institute of Mental Health (NIMH)
Country United States 
Sector Public 
PI Contribution Joint research supervision of fellowship
Collaborator Contribution Hosting and cosupervising WT clinical research fellow
Impact None yet-fellow was on maternity leave
Start Year 2015
 
Description Neuroscience stem cell PhD collaboration 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Knowledge of stem cell neuroscience and analysis
Collaborator Contribution Knowledge of phenotyping
Impact Ongoing research
Start Year 2014
 
Description PGC 
Organisation Psychiatric GWAS Consortium (PGC)
Country Global 
Sector Academic/University 
PI Contribution We contribute to the international Psychiatric Genetics Consortium PGC-data, analysis, initating new papers and helping with co-ordination. AThapar was the ADHD representative for the Cross Disorders Group for 2 years. We remain active contributors to the PGC ADHD group
Collaborator Contribution PGC involves the largest world wide psychiatric genetics collaboration and data set. This allows us access to the data set for hypothesis generation
Impact Research papers as recorded under publications. PhD studentship data.
Start Year 2008
 
Description PGC 
Organisation Psychiatric GWAS Consortium (PGC)
Country Global 
Sector Academic/University 
PI Contribution We contribute to the international Psychiatric Genetics Consortium PGC-data, analysis, initating new papers and helping with co-ordination. AThapar was the ADHD representative for the Cross Disorders Group for 2 years. We remain active contributors to the PGC ADHD group
Collaborator Contribution PGC involves the largest world wide psychiatric genetics collaboration and data set. This allows us access to the data set for hypothesis generation
Impact Research papers as recorded under publications. PhD studentship data.
Start Year 2008
 
Description PTSD and psychosis 
Organisation Lancaster University
Country United Kingdom 
Sector Academic/University 
PI Contribution Preparation of grant application
Collaborator Contribution n/a
Impact Grant application
Start Year 2015
 
Description PTSD and psychosis 
Organisation University of Liverpool
Country United Kingdom 
Sector Academic/University 
PI Contribution Preparation of grant application
Collaborator Contribution n/a
Impact Publication
Start Year 2015
 
Description PTSD and psychosis 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution Preparation of grant application
Collaborator Contribution n/a
Impact Grant application
Start Year 2015
 
Description Pilot study, exosomes in MS plasma 
Organisation Cardiff Metropolitan University
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of biological samples and clinical data.
Collaborator Contribution Provision of biochemical and genomic analysis.
Impact For publications, either published or in process.
Start Year 2017
 
Description Psychiatric Genetics Consortium 
Organisation Psychiatric Genomics Consortium (PGC)
Country Global 
Sector Learned Society 
PI Contribution I am a PI in the PGC and lead the PGC Cognition in Schizophrenia sub-group as well as lead the treatment-resistant schizophrenia analytic group
Collaborator Contribution This is an international collaboration of hundreds of investigators. Within the cognition group we have been joined by 8 other groups and 12 investigators. In the treatment-resistant schizophrenia group there are another 14 investigators
Impact Biological insights from 108 schizophrenia-associated genetic loci Schizophrenia Working Group of the Psychiatric Genomics Consortium Nature 511 (7510), 421-427
Start Year 2015
 
Description Psychosis epidemiology 
Organisation Mount Sinai Hospital (USA)
Country United States 
Sector Hospitals 
PI Contribution Preparation & submission of grant applications
Collaborator Contribution n/a
Impact Publications
Start Year 2015
 
Description Recruitment of psychiatric patients in Bulgaria 
Organisation Medical University of Sofia
Department Psychiatry
Country Bulgaria 
Sector Academic/University 
PI Contribution I provide research expertise, supervise the project and enter the data into a database.
Collaborator Contribution The collaborators recruit and rate the participants
Impact none yet
Start Year 2012
 
Description Renishaw - testing of CED device for Cell delivery 
Organisation Renishaw PLC
Country United Kingdom 
Sector Private 
PI Contribution Intellectual property supporting cell therapy delivery Model generation Device Testing
Collaborator Contribution Supply of research grade devices Knowledge on in-vitro gel testing
Impact papers in preparation
Start Year 2016
 
Description Repeat analysis in next generation sequencing data 
Organisation National Institute for Health Research
Department UCLH/UCL Biomedical Research Centre
Country United Kingdom 
Sector Public 
PI Contribution Analysis of next generation sequencing data
Collaborator Contribution provision of next generation sequencing data from subjects with dementias
Impact ARUK pilot funding award ARUK-PPG2018A-015
Start Year 2017
 
Description Repeat analysis in next generation sequencing data 
Organisation National Institutes of Health (NIH)
Department National Institute of Neurological Disorders and Stroke (NINDS)
Country United States 
Sector Public 
PI Contribution Analysis of next generation sequencing data
Collaborator Contribution provision of next generation sequencing data from subjects with dementias
Impact ARUK pilot funding award ARUK-PPG2018A-015
Start Year 2017
 
Description Rutter text book 
Organisation National Institutes of Health (NIH)
Department National Institute of Mental Health (NIMH)
Country United States 
Sector Public 
PI Contribution Lead editor of the Rutter text book
Collaborator Contribution co lead editor of the Rutter text book
Impact The Rutter text book was published in 2015
Start Year 2012
 
Description STRATA 
Organisation University of Sao Paulo
Department Institute of Psychiatry
Country Brazil 
Sector Academic/University 
PI Contribution work stream lead for multisite MRC stratified medicine study
Collaborator Contribution they have led on project
Impact grant started Oct 2014
Start Year 2013
 
Description SerCymru Fellowship 
Organisation Government of Wales
Country United Kingdom 
Sector Public 
PI Contribution Supervising a Research Fellow. Project title: Deconvoluting the dementia phenotype using functional genomics and computational approaches
Collaborator Contribution Funding the project
Impact This is a multidisciplinary collaboration between biological sciences and informatics/statistic. We have gained assess to EBI data resources which will be analyzed within the scope of the project.
Start Year 2017
 
Description Somatic expansion of simple repeats 
Organisation University of Glasgow
Department Institute of Molecular Cell and Systems Biology
Country United Kingdom 
Sector Academic/University 
PI Contribution Identifying subjects with specific variants for analysis using methods available in Glasgow
Collaborator Contribution Analysis of repeat lengths using next generation sequencing technology
Impact none yet multidisciplinary, bioinformatics, statstics, molecular biology, genetics
Start Year 2017
 
Description Synaptic signalling in neuropsychiatric disorders 
Organisation University of Edinburgh
Department Centre for Clinical Brain Sciences (CCBS)
Country United Kingdom 
Sector Academic/University 
PI Contribution Test whether novel sets of genes relevant to synaptic function (e.g. synaptic signalling complexes characterised via proteomics) are enriched for genetic variants associated with neuropsychiatric disorders.
Collaborator Contribution Access to unpublished molecular neuroscience data (e.g. proteomic data for complexes derived from TAP-tagged synaptic proteins).
Impact Multi-disciplinary: molecular neuroscience, psychiatric genetics PMID: 22083728
Start Year 2010
 
Description Tabrizi 
Organisation University College London
Department Institute of Neurology
Country United Kingdom 
Sector Academic/University 
PI Contribution Statistical pathway analysis of RNA-seq data in HD patients
Collaborator Contribution Data to test analysis methods
Impact No outcomes yet.
Start Year 2015
 
Description Takeda 
Organisation Takeda Pharmaceutical Company
Country Global 
Sector Private 
PI Contribution This collaboration aims to identify new drug targets from genomic data generated by our research groups.
Collaborator Contribution Funding
Impact none as yet
Start Year 2019
 
Description The DNA damage response in Huntington's disease 
Organisation University of Cambridge
Department Gurdon Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution Generation of an assay for repeat analysis in cells and mice.
Collaborator Contribution Expertise and compounds to probe the DDR. Generation of gene-edited mice for crossing with Huntington's model mice.
Impact No outputs yet.
Start Year 2015
 
Description UK Biobank neurodenerative disease platform 
Organisation King's College London
Department NIHR Biomedical Research Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Named investigator on grant application
Collaborator Contribution co-investigators on grant application
Impact Grant application currently under review
Start Year 2013
 
Description UK Biobank neurodenerative disease platform 
Organisation University College London
Department Dementia Research Centre (DRC)
Country United Kingdom 
Sector Academic/University 
PI Contribution Named investigator on grant application
Collaborator Contribution co-investigators on grant application
Impact Grant application currently under review
Start Year 2013
 
Description UK Biobank neurodenerative disease platform 
Organisation University College London
Department Institute of Neurology
Country United Kingdom 
Sector Academic/University 
PI Contribution Named investigator on grant application
Collaborator Contribution co-investigators on grant application
Impact Grant application currently under review
Start Year 2013
 
Description UK Biobank neurodenerative disease platform 
Organisation University of Oxford
Department Department of Physiology, Anatomy and Genetics
Country United Kingdom 
Sector Academic/University 
PI Contribution Named investigator on grant application
Collaborator Contribution co-investigators on grant application
Impact Grant application currently under review
Start Year 2013
 
Description Utilising Adoption-Based Research Designs to Examine the interplay between family relationship processes and child development outcomes 
Organisation University of Oregon
Department PSY Department of Psychology
Country United States 
Sector Academic/University 
PI Contribution scientific input to design of grant and ongoing papers
Collaborator Contribution scientific input to design of grant and ongoing papers
Impact ESRC Secondary Data Initiative: Joint grant application to the ESRC (University of Sussex, Cardiff University, University of Oregon, The Penn State University). Application title: Utilising Adoption-Based Research Designs to Examine the interplay between family relationship processes and child development outcomes
Start Year 2013
 
Description Utilising Adoption-Based Research Designs to Examine the interplay between family relationship processes and child development outcomes 
Organisation University of Sussex
Department School of Psychology Sussex
Country United Kingdom 
Sector Academic/University 
PI Contribution scientific input to design of grant and ongoing papers
Collaborator Contribution scientific input to design of grant and ongoing papers
Impact ESRC Secondary Data Initiative: Joint grant application to the ESRC (University of Sussex, Cardiff University, University of Oregon, The Penn State University). Application title: Utilising Adoption-Based Research Designs to Examine the interplay between family relationship processes and child development outcomes
Start Year 2013
 
Description WT Clinical fellowship 
Organisation Wellcome Trust
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution I will be contributing to the supervision of a Clinical Research Fellow. Project title: Stratification of bipolar disorder: harnessing clinical heterogeneity and genetics shared with other disorders
Collaborator Contribution The WT has funded the fellowship
Impact Allardyce J, , Escott-Price V (2017) Psychosis and the level of mood incongruence in Bipolar Disorder are related to genetic liability for Schizophrenia. JAMA Psychiatry (10.1101/160119)
Start Year 2017
 
Title Diagnosis of Alzheimer's Disease 
Description The work has also been published and has achieved a huge amount of media coverage. This discovery of three further genes associated with Alzheimer's disease could provide valuable new leads in the race to find treatments and possibly cures for the devastating condition. This patent application resulted from Julie Williams, Professor of Neuropsychological Genetics and Professor Mike Owen, Professor and Head of MRC Centre, completing the largest-ever joint Alzheimer's disease genome-wide association study (GWAS) involving 16,000 individuals. The patenting of theseSNPS is still in progress and a reveiew is currently underway to identify the best route to exploitation of the technology. 
IP Reference WO2011001135; NZ 596614; CAN 2,766,876; JP 2012-516841 and JP 2013-164509 ;AUS 201001208; US 13/376,485 and US 13/886,473; EP 10747062.7; CN 201080029259.9 and CN 201310280889.9; HK 12110195.8; UK 2766876 
Protection Patent granted
Year Protection Granted 2012
Licensed No
Impact This has had huge worldwide impact through media coverage and was originally highlighted in the press with the discovery of an additional 5 genes. We are currently in the process of seeking a licencee for the patented technology which encompasses a diagnostic test for the protected gene SNPs. Recent advances include generation of a polygenic score including the licensed SNPs for the detection of AD risk. We are working together with industry on basic genetic testing, cohort studies, cognitive test providers and pathway specific therapies for new ways in which to combat Alzheimer's disease.
 
Title ALIGATOR 
Description ALIGATOR is a Fortran program for testing the enrichment of biological pathways in summary statistics from a genome-wide association study (GWAS). 
Type Of Technology Software 
Year Produced 2009 
Impact ALIGATOR has been widely used to analyse GWAS data. In particular, we used it to highlight involvement of immune pathways in Alzheimer's disease, which has proved to be the basis for a number of grants to follow up the results. 
 
Title Dementia's Platform UK Biostatistics Tool 
Description Bespoke analysis tool to perform the latest analyses on the largest UK datasets available. 
Type Of Technology Software 
Year Produced 2016 
Impact Product still under development / improvement following user feedback. 
 
Title Dementia's Platform UK Cohort Selection Tool 
Description Used to select cohorts of interest, and to put a research proposal to them for feedback under the DPUK research protocol. 
Type Of Technology Webtool/Application 
Year Produced 2016 
Impact Improvements ongoing to develop impacts. 
URL http://www.dementiasplatform.uk/cohort-tools/
 
Title POLARIS 
Description We developed a novel approach to genetic set-based analysis and polygenic risk scoring, which accounts for linkage disequilibrium between SNPs and informs the analysis with previously reported effect sizes of a SNP's association to disease. We call this method POLARIS: POlygenic Linkage disequilibrium-Adjusted RIsk Score. 
Type Of Technology Software 
Year Produced 2017 
Open Source License? Yes  
Impact NA 
URL https://github.com/BakerEA/POLARIS
 
Description 27/04/17 - 2 day symposium, Cardiff 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Other audiences
Results and Impact TWO-DAY SYMPOSIUM ON `NEUROPLASTICITY AND SYNAPTIC FUNCTION IN NEUROPSYCHIATRIC DISORDERS'
Year(s) Of Engagement Activity 2017
 
Description "Genetics of schizophrenia - where to go next?" 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Gave talk at European Congress of Psychiatry entitled "Genetics of schizophrenia - where to go next?"
Year(s) Of Engagement Activity 2015
 
Description "The Nature of Schizophrenia" 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Undergraduate students
Results and Impact Gave a talk at UCL entitled "The Nature of Schizophrenia"
Year(s) Of Engagement Activity 2015
 
Description 01/02/18 - MQ mental health science meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact MQ mental health science meeting - "Psychiatric genetics: implications for prevention and early intervention."
Year(s) Of Engagement Activity 2018
 
Description 02/03/17 - Llandough lecture series 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact Llandough lecture series - "Psychiatric Genetics: Implications for treatment, prevention and personalised medicine."
Year(s) Of Engagement Activity 2018
 
Description 02/06/17 - Neuroscience in Bordeaux Association 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Neuroscience in Bordeaux Association talk - Genomics and the Nature of Schizophrenia.
Year(s) Of Engagement Activity 2017
 
Description 09/10/17 - Stanley Center Biennial Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Stanley Center Biennial Symposium SEVERE MENTAL ILLNESS: FROM GENES TO MODELS TO MECHANISM - talk, "Identifying and exploiting risk alleles in psychosis'. "
Year(s) Of Engagement Activity 2017
 
Description 10/07/17 - NIMH Psychiatric Genomics in the Era of Team Science Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact NIMH Psychiatric Genomics in the Era of Team Science Symposium
Year(s) Of Engagement Activity 2017
 
Description 11 new susceptibility genes linked with Alzheimer's disease 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact In the largest ever study of its kind, an international collaboration of scientists, jointly led by Cardiff, has uncovered 11 new susceptibility genes linked with Alzheimer's disease.


Worldwide TV and Newspaper Coverage received
Year(s) Of Engagement Activity 2013
 
Description 11/05/17 - St George's Tooting talk 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact St George's Tooting talk - "Genetics of Mental Illness "
Year(s) Of Engagement Activity 2017
 
Description 14/06/17 - MRC Symposium - The Developing Brain in Health and Disease 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact MRC Symposium - The Developing Brain in Health and Disease - talk "Schizophrenia and neurodevelopmental continuum"
Year(s) Of Engagement Activity 2017
 
Description 15/09/17 - European Conference on Schizophrenia Research 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact European Conference on Schizophrenia Research - "Genomics and the Nature of Schizophrenia"
Year(s) Of Engagement Activity 2017
 
Description 2013 Open Day 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Undergraduate students
Results and Impact 150 people attended an open day which included a series of talks, poster presentations, lab tours and informal question and answer sessions.

The event was featured on the BBC Radio Wales Science Cafe Show which resulted in increased enquiries from members of the public.
Year(s) Of Engagement Activity 2013
URL http://www.alzheimersresearchuk.org/news-detail/10941/Public-invited-to-day-of-dementia-talks-tours-...
 
Description 2014 Brain & Behavior Research Foundation Ruane Prize for Child and Adolescent Psychiatry 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Education and Information
Year(s) Of Engagement Activity 2014
URL http://youtu.be/1k82NwFc2_Y
 
Description 22q11 syndrome All-Party Parliamentary Group launch 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Attended 22q11 syndrome All-Party Parliamentary Group launch
Year(s) Of Engagement Activity 2015
 
Description 24/01/18 - Exeter Uni talk 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact "Psychosis Genomics: Discovery and Exploitation" talk given at University of Exeter Medical School
Year(s) Of Engagement Activity 2018
 
Description 25th Neuropharmacology Conference 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Attended the 25th Neuropharmacology Conference in Chicago
Year(s) Of Engagement Activity 2015
 
Description 26/06/17 - RCPsych International Congress 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact RCPsych International Congress - talk, "Genes, schizophrenia and treatment response"
Year(s) Of Engagement Activity 2017
 
Description 31/05/17 - Mediterrean Maudsley Forum 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Mediterrean Maudsley Forum - talk "Is the Genetics Revolution here at last: The success of the Psychiatric Genetics Consortium"
Year(s) Of Engagement Activity 2017
 
Description 31/10/17 - Oxford University talk, Dept. of Psychiatry 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact Oxford University talk, Dept. of Psychiatry, "The Nature of Schizophrenia"
Year(s) Of Engagement Activity 2017
 
Description 4th International Symposium - Autism spectrum disorders: From Genes to Interventions 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Gave a talk at 4th International Symposium - Autism spectrum disorders: From Genes to Interventions entitled "Schizophrenia, autism and the neurodevelopmental continuum"
Year(s) Of Engagement Activity 2016
 
Description 6th form talk 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Talk to 6th form students at the Royal Grammar School Worcester about a career in science and medicine.
Year(s) Of Engagement Activity 2015
 
Description ADHD Open Day 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact An event for the public to learn more about ADHD, latest findings and how parents and their families can help with research. Adult attendees were 98% satisfied with the event and there was a likelihood of 87% that they would take part in future research studies. 21.4% of the child attendees said the event was great fun, 21.4% said it was quite good and 57.1% said it was ok.
Year(s) Of Engagement Activity 2016
 
Description ADHD parenting group meeting - ADHD Cardiff - Sharifah Agha 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact Talking about ADHD research and discussing the myths and facts about ADHD
Year(s) Of Engagement Activity 2017
 
Description AMS council meeting 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Attended Academy of Medical Sciences meeting as an elected member of the council
Year(s) Of Engagement Activity 2015
 
Description ART at the Bay 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Presented a talk at the ART at the bay exhibition

Unknown
Year(s) Of Engagement Activity 2013
 
Description ARUK 2014 Annual Meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Type Of Presentation keynote/invited speaker
Geographic Reach National
Primary Audience Other audiences
Results and Impact Julie Williams took part in a debate at the 2014 ARUK conference titled: Alzheimer's disease: The relative importance of Genes and Environment

The conference audience took part in the debate and positive feedback was recieved about this part of the conference.
Year(s) Of Engagement Activity 2014
URL http://www.alzheimersresearchuk.org/conference-programme/
 
Description ARUK Iceland donation press release 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact A press release was issued announcing new funding from ARUK raised by Iceland foods

The press release mentioned research investigating Early Onset AD, this resulted in an increase in enquiries about research
Year(s) Of Engagement Activity 2014
URL http://www.alzheimersresearchuk.org/news-detail/10984/Cardiff-researchers-lead-global-hunt-for-early...
 
Description ARUK Public Engagement event 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact The ARUK event was a meeting of around 100 researchers, clinicians, family members and carers involved with Alzheimers disease, with the purpose of informing people of the research being performed in Cardiff.
Year(s) Of Engagement Activity 2015
 
Description ARUK Public Engagement open day 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Public engagement
Year(s) Of Engagement Activity 2015
 
Description ARUK Roundtable 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact I have been invited and participated in a Roundtable discussion organized by Alzheimer's Research UK: "Where now for Alzheimer's disease research? Learning from recent clinical trials failures and planning for the future", 19 January, 2017
Year(s) Of Engagement Activity 2017
 
Description ARUK Scientific meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact Scientific meeting
Year(s) Of Engagement Activity 2015
 
Description ARUK grant board 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact To decide which research applications ARUK should fund.
Year(s) Of Engagement Activity 2015
 
Description ARUK public event 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact To communicate our research on dementia to the public.
Year(s) Of Engagement Activity 2015
 
Description Advances Wales 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Overview of ECHO Study/CNV research lead